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 The Gram-negative bacterium Francisella tularensis is the causative agent of tularemia 
and a model intracellular pathogen. It is also considered a potential bioweapon, as F. tularensis 
is highly infectious and has the potential to cause fatal disease in humans. Many factors 
required for F. tularensis virulence have been identified, yet we know relatively little regarding 
how these factors are regulated at the level of transcription. In order to further understand the 
regulation of virulence factors in F. tularensis, we have systematically determined the genomic 
regions associated with all of the transcription factors implicated in virulence using chromatin 
immunoprecipitation coupled with high-throughput DNA sequencing (ChIP-Seq).  
We have determined that three transcription factors critical for intracellular growth and 
survival, MglA, SspA, and PigR, are found at virtually all promoters and that PigR, a putative 
DNA-binding protein, requires MglA in order to specifically associate with promoters. We have 
identified a DNA sequence found in promoters positively regulated by PigR, which may 
constitute a PigR-responsive element. Our results indicate that PigR appears to function solely 
as a positive regulator in combination with the complex formed by MglA and SspA, but that 
MglA (as part of the MglA-SspA complex) appears also to function as a negative regulator of 
gene expression, working independently of PigR to negatively regulate σ32-controlled genes.  
By correlating the locations of virulence-associated transcription factor ChIP-Seq peaks 
with nearby genes, we have predicted potential regulons under the control of each factor and, in 
	   iv 
the case of OxyR and the LysR-type transcription regulator FTL_0040, we have determined 
which putative regulon members have been implicated as virulence factors. We have 
determined that the virulence-associated transcription factor PmrA may promote expression 
from genes on the Francisella pathogenicity island indirectly. We have found that three proteins, 
PmrA, IclR, and the LysR-type transcription regulator FTL_1568, associate with regions of the 
genome that are not typical for canonical transcription regulators; we propose that they may 
function in part to organize the chromosome as nucleoid-associated proteins. Finally, we have 
generated a model of the network of transcription factors that control virulence in F. tularensis. 
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The disease tularemia was first characterized in 1911, after an outbreak of a plague-like 
disease was observed in small rodents in Tulare County, CA, USA (McCoy and Chapin, 1912). 
The causative bacterium was isolated and originally named Bacterium tularense (McCoy, 1911). 
Later, the genus of the causative bacterium was renamed Francisella in honor of Dr. Edward 
Francis, a physician and member of the United States Public Health Service (Dorofe'ev, 1947; 
Jellison, 1972). Dr. Francis both named the disease and performed much of the pioneering work 
on tularemia, although it should be noted that in some literature from the mid-20th century, F. 
tularensis was occasionally referenced as Pasteurella tularensis (Jellison, 1972).  
  
F. tularensis subspecies and strains 
There are four subspecies of F. tularensis, all of which are capable of causing disease, 
albeit with significant variability in severity (Ellis et al., 2002): tularensis, holarctica, mediasiatica, 
and novicida.   
Strains of F. tularensis subsp. tularensis, which are also referred to as type A strains, are 
the most pathogenic of the subspecies (Evans, 1985). Fewer than ten F. tularensis subsp. 
tularensis bacteria can constitute an infectious dose, and in humans there are reports of 
mortality rates for untreated disease up to 60% (Tärnvik and Chu, 2007). F. tularensis subsp. 
tularensis is endemic to North America (Keim et al., 2007). The strain most frequently used by 
laboratories to study F. tularensis subsp. tularensis is the sequenced strain SCHU S4 (Larsson 
et al., 2005).  
 F. tularensis subsp. holarctica, also known as type B strains, are the other cause of 
tularemia in humans, although the disease caused by these strains is significantly milder and 
not thought to be life-threatening (Keim et al., 2007). F. tularensis subsp. holarctica is found in 
both North America and Eurasia (Keim et al., 2007). The former Soviet Union used F. tularensis 
subsp. holarctica to attempt to generate a vaccine strain, starting in the 1930s (Tärnvik and 
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Berglund, 2003). They were successful in generating several strains attenuated for virulence in 
humans, and one was transferred to the United States in 1956 (Ellis et al., 2002). This strain, 
called the Live Vaccine Strain (LVS, hereafter referred to as F. tularensis LVS) is frequently 
used as a model to study F. tularensis pathogenesis as cells of this strain are still lethal to mice 
(Eigelsbach and Downs, 1961). All the studies performed on F. tularensis in this work have 
been performed with F. tularensis LVS.  
The F. tularensis subsp. mediasiatica is reported to both have a similar lethal dose in 
animal models and cause disease in humans similar to F. tularensis subsp. holarctica (Larsson 
et al., 2009; Olsufjev and Meshcheryakova, 1983), but is only found in an isolated geographical 
region in Central Asia (Oyston et al., 2004). As a result, there are few studies performed on this 
particular subspecies.  
 Originally classified as its own Francisella species, F. tularensis subsp. novicida is now 
generally considered a subspecies of F. tularensis based on its genetic similarities with the 
other subspecies (Santic et al., 2006), although we will continue to refer to it in this work as F. 
novicida. F. novicida does not cause disease in immunocompetent humans, although the 
disease it causes in animal models is very similar to the disease caused by the human 
pathogens (Ellis et al., 2002; Hollis et al., 1989). Thus, the F. novicida sequenced strain U112 is 
frequently used as a model for F. tularensis subsp. tularensis.  
 
Tularemia 
 Infection by F. tularensis can occur via a number of routes. Contact with, or ingestion of, 
contaminated food, water, or infected animal tissue can all cause disease (Sjöstedt, 2007). 
Arthropod vectors, which include fleas, ticks, biting flies, and mosquitoes, can transmit F. 
tularensis (Petersen et al., 2009). Additionally, F. tularensis is easily aerosolized and infection 
can occur from inhalation of particulate matter from infected carcasses or even dust from 
contaminated soil, grain, or hay (Sjöstedt, 2007).  
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The disease caused by exposure to F. tularensis generally has an incubation period of 
3-5 days, although it may extend up to 21 days (Tärnvik and Berglund, 2003). The disease 
generally manifests with flu-like symptoms; fever, chills, fatigue, general body aches, 
headaches, and nausea are all commonly reported (Evans et al., 1985; Tärnvik and Chu, 2007). 
The type of disease and additional symptoms vary dependent upon the site of infection. The two 
most common types of tularemia are ulceroglandular and respiratory (Nigrovic and Wingerter, 
2008).  
Exposure through a break in the skin, commonly via an infected biting arthropod, causes 
ulceroglandular tularemia. In this case, a papule develops at the site of infection that generally 
becomes a pustule over the course of several days (Evans et al., 1985). As this occurs, lymph 
nodes become swollen and enlarged. While the initial ulcer generally heals even without 
treatment, the lymph nodes can continue to enlarge and potentially become suppurative 
(Tärnvik and Berglund, 2003). Ulceroglandular tularemia is similar in the case of infection with 
either type A (F. tularensis subsp. tularensis) or type B (F. tularensis subsp. holarctica) strains.  
Respiratory tularemia occurs after inhalation of aerosolized bacteria, and symptoms and 
outcome are significantly different upon infection by type A or type B strains (Tärnvik and 
Berglund, 2003). Type B strains generally result in mild, non-fatal respiratory disease. 
Respiratory tularemia with a type A strain, however, is an acute, severe disease with variable 
flu-like symptoms including those listed above, high fever, cough, and dyspnoea (difficulty 
breathing) (Evans et al., 1985; Tärnvik and Berglund, 2003). Without antibiotic treatment, 
mortality rates of 30-60% are reported (Dennis et al., 2001). With treatment, however, mortality 
rates are less than 2% (Dennis et al., 2001).  
Treatment of F. tularensis is typically successful with antibiotics, specifically 
aminoglycosides, tetracyclines, and more recently, quinolones (Tärnvik and Chu, 2007). 
Development of antibiotic-resistant Francisella within patients is not a significant concern, as it is 
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not a member of the commensal flora and there is no evidence that it can be spread via human-
to-human contact.  
 
Classification as a potential bioweapon 
Not only is F. tularensis extremely infectious, it also has a history of development as a 
bioweapon, in the 1930s by the Japanese biological warfare program (Harris, 1992), and later 
by both the United States and the former Soviet Union (Dennis et al., 2001). The United States 
cancelled their biological weapons program and signed the Convention on the Prohibition of the 
Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and 
their Destruction in 1972 (Oyston et al., 2004). Given its history as a developed bioweapon, its 
highly infectious nature, the large number of transmissible routes, and its potential to cause 
mortality, the United States government considers F. tularensis a potential bioweapon.  
 
Intracellular lifestyle 
 As an intracellular pathogen, F. tularensis must be able to enter the cell, survive the 
hostile eukaryotic intracellular environment, replicate, and escape to continue the infection. 
While F. tularensis is competent to infect a number of different cell types, the macrophage 
appears to be a critical niche of infection for subsequent dissemination (Councilman and Strong, 
1921; White et al., 1964). A critical function of macrophages is to phagocytose and destroy 
potential pathogens. However, F. tularensis has co-opted this function in order to gain access to 
the cell. F. tularensis promotes its own phagocytosis by inducing formation of a looping 
pseudopod which eventually engulfs the bacterium (Clemens et al., 2005) (Figure 1.1). Most 
phagocytosed vacuoles would merge with early, and then late, endosomes, become acidified, 
and fuse with lysosomes. The environment inside the vacuole is toxic and the inactivated 
contents would be recycled. Experimental evidence thus far suggests that the fate of the F. 
tularensis-containing phagosome (FCP) depends on the state of the bacteria prior to uptake. If 
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the F. tularensis were opsonized prior to phagocytosis, the FCP does not become acidified and 
the bacteria escape into the cytoplasm between 2-4 hours post-infection (Clemens et al., 2009; 
Jones et al., 2012). If the F. tularensis were unopsonized when phagocytosed, the FCP 
becomes transiently acidified and the bacteria escape into the cytoplasm in less than 1 hour 
(Jones et al., 2012; Santic et al., 2007). Once in the cytoplasm, the bacteria replicate to high 
numbers and, after 24-72 hours, trigger apoptosis of the cell, escaping to continue infection 









Figure 1.1. F. tularensis is an intracellular pathogen. Diagram depicts the intramacrophage growth of 
F. tularensis. Bacteria are engulfed via looping pseudopods and enter a Francisella containing particle 
(FCP, circle with solid brown line). Bacteria are able to escape the FCP (circle with dashed brown line) 
and replicate in the cytosol, eventually triggering cell death to escape the macrophage. However, bacteria 
with mutations in mglA or bacteria missing the FPI cannot escape the FCP and are degraded (circle with 
sold black line). Diagram adapted from Pechous et al., 2009. 
  
7
The Francisella Pathogenicity Island 
The Francisella Pathogenicity Island (FPI) is a genetic region encompassing 
approximately 25-30 kb of the F. tularensis genome and encodes two putative operons (Barker 
and Klose, 2007). A genetic screen performed in F. novicida first identified two genes located on 
the FPI as critical for intramacrophage growth and survival (Gray et al., 2002). That the screen 
was performed in F. novicida was likely critical to the early identification of genes present on the 
FPI; while the genomes of F. tularensis subsp. tularensis and holarctica contain two identical 
copies of the FPI, F. novicida only contains one, which allowed the FPI to be easily identified by 
inactivating mutagenesis (Nano et al., 2004).  
The region that comprises the FPI is likely to have been horizontally acquired, as the 
GC-content of the region is extremely low in comparison to the low GC-content of the rest of the 
genome (27% vs 32%) (Nano and Schmerk, 2007). There are 16 genes which comprise the 
conserved core of the FPI (Figure 1.2), all of which are found in both F. tularensis LVS and 
sequenced F. tularensis subsp. holartica clinical strains (Bröms et al., 2010). With the exception 
of pdpE, all of the FPI genes have been demonstrated to be important for virulence in animal 
models (Bröms et al., 2010). Upstream of iglA, F. tularensis subsp. tularensis and novicida 
contain two additional genes, pdpD and anmK (Bröms et al., 2010). It has been shown that the 
pdpD gene in F. novicida is critical for virulence, and that the presence of the anmK gene, which 
is furthest upstream, is also critical, although possibly only because its promoter may be used 



















 The FPI locus is required for intramacrophage survival and growth, and it appears to be 
critical specifically for arresting phagosome maturation and escape of the bacteria into the 
cytosol. As many recent studies have indicated that the FPI genes likely encode a type VI 
secretion system (T6SS) (Barker and Klose, 2007; Barker et al., 2009; Brotcke et al., 2006; 
Bröms et al., 2011; de Bruin et al., 2011; 2007; Lindgren et al., 2013; Nano et al., 2004; Santic 
et al., 2007), this most likely occurs via translocation of bacterial effector proteins to directly 
modulate host cell pathways. However, the homology between the FPI and other described 
T6SSs is limited; the FPI appears to be only distantly related to other well-studied T6SSs 
(Barker et al., 2009; Bingle et al., 2008; de Bruin et al., 2007). Recently, the crystal structure of 
a putative structural T6SS protein from F. novicida, DotU, was reported and despite the lack of 
strong similarity at the amino acid level, it does appear to have significant structural similarities 
to DotU homologs in other organisms (Robb et al., 2012). Experiments in F. tularensis LVS 
have recently indicated that eight proteins encoded on the FPI, specifically IglE, IglC, IglI, VgrG, 
PdpE, PdpA, IglJ, and IglF, are secreted into macrophages, dependent on the presence of the 
FPI-encoded IglG and DotU proteins (Bröms et al., 2012). It is not known if these secreted 
proteins constitute effectors and many questions remain regarding the structure and function of 
the FPI-encoded proteins in promoting intracellular survival.  
 
RNA polymerase in Escherichia coli and F. tularensis 
Not only is transcription an essential process, but it is also a critical point of regulation for 
most bacterial virulence programs. Transcription occurs through the activity of the highly 
conserved DNA-dependent RNA polymerase (RNAP) enzyme, which is capable of synthesizing 
RNA. In E. coli, the core RNAP consists of multiple subunits: two α subunits, a β subunit, a β’ 
subunit, and an ω subunit. The core enzyme contains all of the catalytic machinery required to 
initiate RNA synthesis, but in order to initiate transcription at specific promoters, core RNAP 
must associate with the σ subunit, which together are called the RNAP holoenzyme. 
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 F. tularensis is unique in that it encodes genes for two distinct α subunits (Charity et al., 
2007); all other bacterial species examined to date contain only one rpoA gene (which encodes 
the α subunit) and incorporate a homodimer of α subunits into RNAP. In F. tularensis, both α 
subunits are incorporated into RNAP in vivo (Charity et al., 2007). In vitro data is consistent with 
both subunits incorporated as heterodimers (Mukhamedyarov et al., 2011).  While the genes 
that encode the two α subunits, rpoA1 and rpoA2, are reported to be potentially essential genes 
(Gallagher et al., 2007), several transposon mutant screens have identified rpoA2 as a factor 
critical for virulence, suggesting that rpoA2 may not be essential (Asare et al., 2010; Su et al., 
2007). 
For most σ factors, binding to the RNAP core enzyme (forming the holoenzyme) induces 
a conformational change in σ such that a specific DNA-binding domain is unmasked. RNAP 
holoenzyme is then competent to recognize, bind, and initiate transcription at promoters 
recognized by RNAP containing the σ factor. Most bacteria encode not only a so-called 
housekeeping σ factor, but also several others, termed alternative σ factors, which are used to 
respond to specific stimuli and initiate the appropriate transcriptional response. It has been 
proposed that the number of σ factors present in a bacterial species increases in relation to both 
its genome size and the complexity of its environment (Pérez-Rueda et al., 2009; van 
Nimwegen, 2003). F. tularensis has a broad host range yet its genome is quite small, encoding 
about 2,000 genes in approximately 1.9 Mb. It contains two genes for σ factors: rpoD, which 
encodes the housekeeping factor σ70, and rpoH, encoding σ32, or the heat-shock σ factor (Grall 
et al., 2009).  
 
The structure of bacterial promoters 
 Promoter regions contain specific sequences of DNA that allow for σ factor recognition 
and subsequent initiation of transcription. These DNA sequences contribute to what is called the 
basal promoter strength, or the frequency with which transcription occurs at the promoter region 
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in the absence of other factors. For many promoters, the majority of the basal activity is 
determined by two 6 bp regions, called the -10 and -35 elements, which are so named due to 
their location, approximately 10 and 35 bp upstream from the transcription start site. The σ 
subunit makes direct contact with these regions of DNA in a sequence-specific manner, such 
that -10 and -35 elements that are closer to the consensus sequence will have more σ binding 
and greater basal promoter strength. While most σ subunits are part of the diverse σ70 family 
and utilize the -10 and -35 elements for promoter recognition, the σ54 family members are 
structurally different; these alternative σ factors recognize specific sequences at -12 and -24 
regions, which are located 12 and 24 bp upstream of the transcription start site, respectively 
(reviewed in Österberg et al., 2011). 
Basal promoter activity is also affected by a number of other factors, including the 
spacing between the -10 and -35 elements and the presence of additional points for RNAP 
holoenzyme contact, which could include a discriminator region, an extended -10 element, or an 
UP element. The discriminator region is found between the transcription start site (also referred 
to as +1) and the -10 element (Travers, 1980). In E. coli and Thermus aquaticus, the presence 
of additional guanines in the discriminator region improves binding of the major σ factor to 
promoters (Feklistov et al., 2006; Haugen et al., 2006). The extended -10 element consists of an 
additional recognized dinucleotide sequence 1 bp upstream of the -10 element (Barne et al., 
1997), found frequently in E. coli promoters with suboptimal -10 or -35 regions (Hook-Barnard et 
al., 2006; Mitchell et al., 2003) and commonly used in Bacillus subtilis (Camacho and Salas, 
1999). The UP element is an approximately 20 bp region typically found in E. coli a few bp 
upstream from the -35 element (Gourse et al., 2000; Ross et al., 1993). In E. coli, the 
consensus UP element is very AT-rich and its presence significantly increases transcription, 
providing another point of contact between DNA and part of RNAP, the C-terminal domain of the 
RNAP α subunit (αCTD) (Gourse et al., 2000).  
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The consensus sequences for the described promoter elements have been determined 
in E. coli, but their similarity to their counterparts in F. tularensis is unknown. There is significant 
conservation between the E. coli σ70 and the F. tularensis σ70 in the regions critical for DNA 
contact, suggesting that the consensus sequences are likely to be similar in these two 
organisms. It should be noted, however, that the canonical elements that E. coli promoters 
consist of are AT-rich. The entire genome of F. tularensis is very AT-rich, which makes 
identifying specific promoter regions, in the absence of other data, more challenging. 
 
σ factor competition 
Each bacterial species encodes at least one housekeeping σ factor, which is thought to 
be both the most abundant and have the highest affinity for core RNAP during normal growth. 
Alternative σ factors can recognize and bind to DNA sequences that are different from the 
housekeeping σ factor recognition sites, so they are often used to specifically regulate particular 
promoters. Alternative σ factors can be used to respond to specific stimuli, via altering the 
transcriptional program to preferentially express genes required to adapt to the given stimulus. 
An example would be the E. coli σ32 factor, the heat-shock σ factor. The mRNA encoding σ32 is 
present at low temperatures, but the translation start site is occluded by complementary base 
pairing, preventing protein synthesis. Under heat stress, the base pairing that prevents the 
synthesis of σ32 is destabilized, thus increasing the abundance of σ32 (Morita et al., 1999). 
Subsequently, part of the σ32-mediated response to heat stress is involved in preventing the 
increase in temperature from damaging DNA; σ32 upregulates genes involved in maintaining 
genome integrity, such as the recombination repair proteins recA and recJ (Nonaka et al., 
2006). 
 In E. coli, the amount of core RNAP enzyme in each cell is thought to remain relatively 
constant, providing a limited pool of core RNAP for association with the available σ factors 
(Grigorova et al., 2006; Piper et al., 2009). The association between core RNAP and a σ factor 
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is dependent on both the affinity of a particular σ factor for core RNAP as well as the abundance 
of the available σ factor. Essentially, σ factors must compete for association with a limited 
amount of core RNAP. Thus, much of the regulation with respect to which σ factor is used can 
be attributed to increasing or decreasing the concentration of a σ factor, which is in fact a highly 
regulated process (Österberg et al., 2011). In the absence of specific signals for alternative σ 
factor use, there are a number of dedicated factors, termed anti-σ factors, which are responsible 
for interacting with and sequestering specific σ factors (reviewed in Helmann, 1999). But 
regulating the abundance of an available σ factor can be used in concert with another strategy 
to allow alternative σ factor use, such as specifically promoting the formation of RNAP 
containing a particular σ factor by utilizing a protein that interacts with a σ factor such as Crl. 
 The protein Crl was identified based on its ability to promote transcription from σ38-
dependent promoters in E. coli (Pratt and Silhavy, 1998). It has subsequently been found to 
achieve this effect by interacting directly with σ38 and apparently promotes the formation of σ38-
containing RNAP holoenzyme (Gaal et al., 2006; Banta et al., 2013). This appears to effectively 
allow even low concentrations of the alternative sigma factor σ38 to associate with core RNAP 
when in competition with other σ factors (Gaal et al., 2006; Banta et al., 2013). Crl sets the 
precedent in the literature for a transcription factor that appears to specifically and directly 
promote formation of a particular RNAP holoenzyme species to control gene expression.  
 
Regulators of virulence gene expression in F. tularensis 
MglA and SspA 
 MglA and SspA are two proteins that have been found to be critical for F. tularensis 
intracellular survival and replication (Baron and Nano, 1998; Charity et al., 2007). Both are 
members of the stringent starvation protein A (SspA) family, classified based on homology to 
the E. coli transcription factor SspA. In E. coli, SspA is a protein produced during the stringent 
response, the response to amino acid starvation (Williams et al., 1994). The stringent response 
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is characterized by decreased transcription from rRNA promoters, limited protein production, 
and increased abundance of the small molecule ppGpp (guanosine 3',5'-bisdiphosphate, with its 
precursor pppGpp [collectively referred to here as (p)ppGpp]) (reviewed in Jin et al., 2012). 
Despite the significant decrease in protein production, the amount of SspA present in the cell 
increases during the stringent response (Williams et al., 1994). The crystal structure of the SspA 
homolog in Yersina pestis has been determined and SspA protein was found as a homodimer 
(Hansen et al., 2005).  It has been shown that SspA, in a complex with a co-activator protein 
Lpa, can associate with σ70-containing RNAP to positively regulate the expression of 
bacteriophage P1 late genes, although the mechanism by which this occurs is unclear (Hansen 
et al., 2003). No putative DNA-binding domains are present in SspA and none were reported in 
the crystal structure for the Y. pestis homolog of SspA (Hansen et al., 2005). Thus, it seems 
likely that the effect of SspA on P1 late gene expression is due to its ability to associate with 
RNAP holoenzyme and possibly interact with Lpa, rather than by binding DNA itself. 
MglA and SspA in F. tularensis can interact to form a heteromer and MglA and SspA 
have been shown to directly interact with σ70-containing RNAP, likely as a heteromer (Charity et 
al., 2007). The regulons of MglA and SspA are extensive and virtually identical, and include 
approximately 100 genes (Brotcke et al., 2006; Charity et al., 2007; Guina et al., 2007). 
MglA/SspA regulated genes include many virulence-related genes as well as many which are, 
thus far, unlinked to any virulence phenotype (Brotcke et al., 2006; Charity et al., 2007; Lauriano 
et al., 2004). Among the genes whose expression is most significantly promoted by MglA and 
SspA are genes on the FPI (Brotcke et al., 2006; Charity et al., 2007). MglA and SspA are 
critical for FPI gene expression, and the decrease in FPI gene expression undoubtedly 
contributes to the failure of mglA or sspA mutants to survive intracellularly and contributes to the 
avirulence of mglA and sspA mutants in mice (Baron and Nano, 1998; Brotcke et al., 2006; 
Charity et al., 2007; Lauriano et al., 2004; Nano et al., 2004). The mechanism by which MglA 
and SspA influence gene expression, however, remains unclear.  
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 PigR and (p)ppGpp 
A protein that interacts with the MglA-SspA complex and also regulates a common set of 
genes is called PigR in F. tularensis LVS (FevR in F. novicida) (Brotcke and Monack, 2008; 
Charity et al., 2009). PigR contains a putative helix-turn-helix (HTH) motif and shows homology 
to members of the MerR family of transcription regulators (Brotcke and Monack, 2008; Charity 
et al., 2009). 
PigR contains a putative HTH motif; this putative HTH motif is similar in sequence and 
relative location to the HTH motif found in MerR family proteins (Brotcke and Monack, 2008; 
Charity et al., 2009). The conservation of a similar putative DNA-binding domain between PigR 
and MerR family members suggests that PigR may bind DNA and may be a member of the 
MerR family. MerR family members contain two domains: one domain that contains a highly 
conserved winged HTH motif and another more variable C-terminal domain, which is generally 
the effector-binding domain (Brown et al.). The variable C-terminal domains frequently function 
via binding of co-activators, and a subfamily of MerR regulators (including MerR itself) uses this 
region to specifically interact with and respond to metals (Summers, 2009). The mechanism for 
promoter activation by MerR family members appears to be largely conserved. Target 
promoters identified for canonical MerR family members generally have longer, suboptimal 
spacing (19 or 20 bp) between the -10 and -35 promoter regions. MerR family members 
frequently associate with the promoter region in both the inactive and active form. Upon 
activation, a shift in protein conformation occurs which results in a dramatic bending and 
unwinding of promoter DNA, effectively shortening the distance between the -10 and -35 
elements to allow for efficient holoenzyme recognition (Brown et al.; Newberry and Brennan, 
2004).  
The HTH motif in PigR was identified by comparison with the conserved domain 
cd01104 in the NCBI CDD database. The founding member of this group is the E. coli MerR 
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family member MlrA. MlrA and the other proteins with domains found in the cd01104 group can 
be distinguished from other MerR family members in their lack of an obvious dimerization 
domain, which would typically be found as part of the N-terminal domain after the HTH motif. 
Additionally, studies of MlrA have indicated that it may have a mechanism of promoter activation 
that differs from other MerR family members. MlrA has been found to bind upstream from the -
35 region (from -146 to -113) of its well-described target promoter, csgD (Ogasawara et al., 
2010). Despite the lack of an obvious dimerization domain within the protein, the identified DNA-
binding site consists of a palindrome, suggesting that MlrA could function as a dimer 
(Ogasawara et al., 2010). Although the homology between PigR and MerR family members is 
significant, there is as of yet no evidence that PigR functions as a MerR family member by 
directly binding DNA to influence transcription.  
It has been found, however, that PigR interacts with RNAP via association with the 
MglA-SspA complex (Charity et al., 2009). This interaction appears to be influenced by 
(p)ppGpp (Charity et al., 2009). The production of (p)ppGpp in both E. coli and F. tularensis is 
dependent on two enzymes with (p)ppGpp synthetase activity, RelA and SpoT (Charity et al., 
2009). Cells that lack PigR or that lack both RelA and SpoT exhibit reduced FPI gene 
expression and are unable to cause disease in mice (Charity et al., 2009).  
Given that PigR, MglA, and SspA all regulate a common set of genes, we have 
previously hypothesized that PigR is a site-specific DNA-binding protein critical for directing 
MglA-SspA associated RNAP to target promoters and activating transcription by making 
contacts both with the DNA and with the RNAP-associated MglA-SspA complex (Charity et al., 
2009). In turn, (p)ppGpp is thought to exert its effects, either directly or indirectly, by promoting 









Figure 1.3. A model for the regulation of target gene expression by PigR, the MglA-SspA 
complex, and (p)ppGpp. PigR, a putative site-specific DNA-binding protein, interacts directly 
with the RNAP-associated MglA-SspA complex at target promoters. The presence of (p)ppGpp 










PmrA is the only protein encoded by F. tularensis LVS with significant similarity to a two-
component system response regulator, although the genomes of F. tularensis SCHU S4 and F. 
novicida encode an additional putative response regulator (FTT1543 and FTN_1453, 
respectively) (van Hoek, 2013). Two-component systems are typically encoded by two genes 
within the same operon and consist of a sensor kinase and a response regulator. Canonically, 
the sensor kinase responds to an environmental stimulus and alters the phosphorylation state of 
the response regulator. The response regulator then binds to promoter sequences of regulated 
genes to induce or repress transcription (Stock et al., 2000). Sensor kinases and response 
regulators that are not found together in operons are frequently referred to as orphans. These 
orphan sensor kinases and orphan response regulators may have specific partners, they may 
be able to interact with several partners, or they may have atypical interactions that influence 
gene expression in other ways (reviewed in Raghavan and Groisman, 2010).  
In F. tularensis LVS, there are three putative sensor kinases annotated, none of which 
are found in the same putative operon as pmrA; thus, all the annotated sensor kinases or 
response regulators are considered orphans. However, it should be noted that two of the 
annotated sensor kinases, FTL_1878 and FTL_1879, appear to be incorrectly annotated. The 
sequences of FTL_1878 and FTL_1879 together encode one protein, homologous to the sensor 
kinase annotated as kdpD in F. novicida and F. tularensis subsp. tularensis. In the F. tularensis 
subsp. holarctica species, kdpD contains a premature stop codon and the resulting fragments 
are annotated as two separate sensor kinases (Alkhuder et al., 2010). Thus, it is likely that the 
two annotated sensor kinases FTL_1878 and FTL_1879 that together correspond to kdpD are 
not functional sensor kinases. This leaves one potentially functional sensor kinase in F. 
tularensis LVS, encoded by qseC (FTL_1762).  
Previous studies have demonstrated a link between the transcription factor PmrA and 
virulence (Bell et al., 2010; Mohapatra et al., 2007; Sammons-Jackson et al., 2008). Not only 
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was a pmrA mutant attenuated for replication in macrophages and for virulence in a mouse 
infection model, it was found that PmrA positively regulates a subset of genes controlled by 
MglA, SspA, and PigR, including pigR itself (Mohapatra et al., 2007; Sammons-Jackson et al., 
2008). Additional work in F. novicida indicated that purified PmrA could bind its own promoter, 
as well as the promoter of the FPI gene pdpD, which is present in the F. tularensis subsp. 
tularensis SCHU S4 and F. novicida U112 strains but not in any F. tularensis subsp. holarctica 
strains, including LVS (Bell et al., 2010).  
It is also reported that KdpD is likely to be the cognate sensor kinase for PmrA (Bell et 
al., 2010). However, as previously mentioned, LVS does not appear to contain an intact kdpD 
gene. The effect of PmrA on virulence gene expression does not appear to be strain specific, as 
cells of LVS that contain a deletion of pmrA exhibit a similar downregulation of pigR and other 
MglA/SspA/PigR regulated genes when compared to wild-type cells. Moreover, a LVS pmrA 
mutant is also attenuated for virulence in an animal model (Sammons-Jackson et al., 2008). 
Thus, if PmrA functions in a canonical manner to alter gene expression after phosphorylation by 
a sensor kinase, it appears that QseC, the only potentially functional sensor kinase in LVS, 
would be the likely candidate to interact with PmrA.  
Several other groups have studied PmrA in F. novicida, under the alternative name of 
QseB, in the context of biofilm formation (Durham-Colleran et al., 2010; Zogaj and Klose, 2010). 
A pmrA deletion strain in LVS was found to be attenuated for biofilm formation (Durham-
Colleran et al., 2010). Additional work in F. novicida found PmrA may affect biofilm formation 
through altering the expression of F. novicida-specific genes responsible for controlling bis-(3’-
5’)-cyclic dimeric GMP (cdi-GMP) (Zogaj and Klose, 2010). However, no homologs of these 
genes, encoding proteins with either diguanylate cyclase or phosphodiesterase activity, have 
been identified in either F. tularensis subsp. holarctica or F. tularensis subsp. tularensis strains. 
In fact, as biofilm formation phenotypes correlated inversely with virulence phenotypes, it was 
suggested that loss of the ability to generate cdi-GMP is a factor associated with the increased 
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virulence of F. tularensis subsp. holarctica and subsp. tularensis strains in comparison to F. 
novicida (Zogaj et al., 2008).  
 
IclR 
 The IclR family of transcription factors is defined by an N-terminal HTH domain and a 
region of conservation in the C-terminus that may bind to a regulatory substrate (Krell et al., 
2006). Additionally, IclR family members are also defined by the conservation of their overall 
size, ranging from 240-280 amino acids. These family members are widely found and have 
been identified in over 60 genera of bacteria and archaea (Krell et al., 2006). By both promoting 
and/or repressing expression of their target genes, IclR family members also appear to regulate 
a wide variety of cellular processes, including those for metabolic pathways, resistance to small 
molecules, determinants of pathogenicity, and developmental processes such as sporulation 
(Molina-Henares et al., 2006).  
 An F. tularensis IclR protein was identified as being important for virulence in a screen 
that assessed the ability of F. novicida transposon mutants to infect the spleen after 
intraperitoneal injection (Weiss et al., 2007). The mutant containing a transposon insertion in the 
iclR gene was severely attenuated for infection, but in a cell culture model appeared to stimulate 
macrophage cell death faster and induced higher levels of a specific proinflamatory cytokine 
than wild-type F. novicida (Weiss et al., 2007). When used to infect macrophages lacking 
components of the cell death pathway, the mutant containing a transposon insertion in the iclR 
gene failed to both promote cell death and induce levels of the specific proinflamatory cytokine 
(Weiss et al., 2007). This suggests that the IclR protein in F. tularensis subsp. novicida is 
important for the regulation of factors that modulate the host immune response in order to 
promote infection.  
 The effect of IclR on the virulence of F. tularensis appears to be strain-specific, however. 
A study performed on the F. tularensis LVS homolog of IclR found it to be dispensable for 
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replication in macrophages and virulence in animals (Mortensen et al., 2010). Similarly, deletion 
of the F. tularensis subsp. tularensis gene encoding the IclR homolog had no effect on virulence 
in a mouse model, but the authors were able to replicate the attenuation phenotype of the F. 
novicida iclR mutant (Mortensen et al., 2010). Many of the genes found to be regulated by IclR 
in F. tularensis LVS appear to be pseudogenes. The F. tularensis subsp. tularensis homologs of 
the IclR-regulated genes are also pseudogenes, but the F. novicida homologs appear to encode 
functional proteins (Mortensen et al., 2010). This suggests that there are subspecies-specific 




 The ferric uptake regulator, Fur, is a site-specific DNA-binding protein that typically 
functions as a repressor. Fur binds Fe2+ directly, and in its Fe2+-bound state represses 
transcription of target genes under conditions considered iron-replete (Bagg and Neilands, 
1987). Fur binds to a specific sequence on the DNA, termed a Fur box (Baichoo and Helmann, 
2002; de Lorenzo et al., 1987), and prevents transcription by occluding RNAP from the promoter 
region of the target gene. When the cellular concentration of iron is reduced, Fur dissociates 
from regulated promoters to allow transcription (Bagg and Neilands, 1987).  
 In F. tularensis, Fur has been shown to regulate the fsl operon, which encodes a 
siderophore used in ferric iron uptake, in response to iron availability (Buchan et al., 2009; 2008; 
Ramakrishnan et al., 2012). Two Fur boxes are found associated with the operon; one Fur box 
is found upstream of fslA, and the other Fur box is located upstream of flsE, which encodes the 
receptor for the siderophore (Deng et al., 2006; Kiss et al., 2008; Ramakrishnan et al., 2008).  
 Multiple studies have linked iron concentration to virulence gene expression in F. 
tularensis (Buchan et al., 2008; 2009; Deng et al., 2006; Lenco et al., 2005). Many other 
bacteria increase virulence gene expression upon sensing low iron conditions, consistent with 
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the idea that the intracellular environment in host cells is iron-limited (Andrews et al., 2003; 
Caza and Kronstad, 2013). In F. tularensis, it has been demonstrated that the levels of FPI-
encoded proteins IglC and PdpB, as well as a number of FPI-encoded transcripts, are increased 
when cells are grown in low iron conditions (Deng et al., 2006; Lenco et al., 2005). The increase 
in protein and transcript abundance that appears to occur under conditions of low iron is 
suggestive of regulation by Fur; thus, the promoter regions of affected genes on the FPI were 
inspected for putative Fur boxes, which were identified (Deng et al., 2006).  
To test the effect of the Fur protein on the expression of FPI genes, one of the FPI 
genes with increased transcription under low iron conditions, iglB, was examined using a 
reporter construct. While expression of an iglB-lacZ reporter increased in response to low iron, it 
was not repressed by overexpression of Fur, unlike an fslC-lacZ reporter (Buchan et al., 2008; 
2009). Another gene in the Fur-regulated fsl operon, fslA, was examined in the context of both 
low iron conditions and in cells with an insertion mutation in the fur gene. In both low iron 
conditions and in cells with a mutation in fur, fslA-lacZ expression increased, consistent with the 
repression of fslA by Fur in iron-replete conditions (Buchan et al., 2009). Expression of another 
FPI gene reporter construct, iglA-lacZ, showed moderate increases in low iron conditions. 
However, expression of the iglA-lacZ reporter also continued to increase in response to low iron 
conditions in a fur mutant background (Buchan et al., 2009). This suggests that the promoter 
driving expression of iglA and iglB may respond to iron abundance independently of Fur. There 




 OxyR is a LysR-type transcription regulator used to mediate the cellular response to 
oxidative stress—specifically the presence of hydrogen peroxide (reviewed in Imlay, 2013). The 
effect of OxyR as an activator or a repressor depends upon the spacing between the OxyR 
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binding site and the promoter elements. OxyR binds DNA as a homotetramer, and when 
reduced, binds across five helical turns, with a bend in the DNA in the third turn. Under 
conditions of oxidative stress, OxyR is directly oxidized and undergoes a conformational change 
such that the homotetramer binds across four consecutive helical turns, occupying a slightly 
different DNA binding site (Choi et al., 2001; Toledano et al., 1994).  
In E. coli, OxyR regulates the expression of close to 40 genes (Chiang and Schellhorn, 
2012; Zheng et al., 2001). The OxyR regulon includes the oxyR gene itself, which OxyR 
negatively regulates (Christman et al., 1989; Warne et al., 1990), and the oxyS gene which is 
transcribed divergently from the oxyR gene, encodes a regulatory RNA, and is positively 
regulated by OxyR (Altuvia et al., 1997). The presence of OxyR is conserved among diverse 
bacterial species, and OyxR positively regulates the expression of genes encoding catalases 
(such as the hydroperoxidase I, encoded by katG) and alkyl hydroperoxidase reductase (such 
as Ahp, encoded by ahpCF) in many gammaproteobacteria. Catalases and Ahp are used to 
detoxify H2O2 into H2O and O2; their regulation by OxyR provides a direct link between sensing 
and detoxifying H2O2 (reviewed in Imlay, 2008). 
 In F. novicida, OxyR was identified as critical for virulence in a screen of transposon 
insertion mutants that used Drosophila melanogaster as an infection model (Moule et al., 2010). 
The screen also identified genes encoding DNA repair enzymes, suggesting that responding to 
DNA-damaging oxidative stress is a critical aspect of successful infection. In the D. 
melanogaster model, a specific immune response is responsible for generating reactive oxygen 
species; in flies lacking this immune response, the F. novicida mutant containing a transposon 
insertion in the oxyR gene was able to successfully survive within the fly (Moule et al., 2010).  
 
Chromosomal organization and nucleoid-associated proteins (NAPs) 
 While the issues surrounding chromosome organization and compaction have been the 
subjects of investigation in eukaryotes for some time, interest in the manner in which bacterial 
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chromosomes are organized has recently increased. Early electron micrograph images 
prompted the theory that bacterial DNA compaction might mostly be achieved though DNA 
supercoiling, in contrast to the histone-mediated organization found in eukaryotes (Kellenberger, 
1988, reviewed in Dame, 2005). While it is clear that supercoiling is critical for DNA organization 
and compaction, it has become widely recognized that proteins not only play a role in 
generating and stabilizing supercoiled DNA, but also in the organization of DNA. A major 
difference between eukaryotic and prokaryotic DNA organization is that prokaryotic DNA is 
generally accessible to the transcription machinery. Some have suggested that the entire 
genome in prokaryotes is available and competent for transcription (Wade et al., 2005), 
although there are studies suggesting that this is not universally true (Dorman, 2004; Myers et 
al., 2013). Regardless, the prokaryotic chromosome appears to be organized in a way that 
allows accessibility yet still maintains an appropriate level of compaction.  
 Evidence for chromosomal organization and plasticity specifically related to transcription 
comes from studying the stringent response in E. coli. Ribosomal RNA operons are among the 
most highly transcribed during normal cell growth in E. coli, and fluorescence microscopy of 
epitope-tagged RNAP subunits reveals distinct foci (reviewed in Jin et al., 2012). These discrete 
foci, termed transcription foci or transcription factories, correspond to rRNA operons and the 
many molecules of RNAP involved in their transcription. During the stringent response, 
however, growth slows, transcription from rRNA and tRNA operons dramatically decreases, and 
the transcription foci are no longer present, suggesting a significant shift in chromosomal 
organization (Jin et al., 2012).  
 A functional class of proteins, nucleoid-associated proteins (NAPs), has been described 
which, critically, are able to alter the trajectory of DNA via bending, wrapping, or bridging DNA 
molecules (Dillon and Dorman, 2010). Given the nature of their interaction with DNA, it is not 
surprising that many NAPs affect transcription. And since NAPs appear to bind DNA at many, 
sometimes extended, sites throughout the chromosome, it is also unsurprising that many are 
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abundant proteins. Well-described NAPs that fit this description, i.e., affect the trajectory of 
DNA, influence transcription, and are abundant, include the proteins H-NS, HU, Fis, and IHF 
(reviewed in Dame, 2005; Dillon and Dorman, 2010). However, the functional class of NAPs has 
extended to include a number of proteins that may or may not be highly abundant and may be 
implicated in a number of other cellular processes. These include MukB, Lrp, CbpA, the Borrelia 
burgdorferi protein EbfC (whose E. coli homolog is YbaB), Dps, Crp, and the Mycobacterium 
tuberculosis protein EspR (Blasco et al., 2012; Dillon and Dorman, 2010; Grainger et al., 2005; 
Jutras et al., 2012). It should be noted that in F. tularensis, the only recognizable NAP identified 
thus far is the homolog of HU, encoded by hupB.  
 Including a protein that has been well-studied as a canonical transcription factor, such as 
Crp, in the NAP category is indicative that the line between transcription factor and NAP is 
becoming increasingly blurred and the distinction less meaningful. The effect of NAPs on 
transcription varies; some, like members of the H-NS family are involved in silencing gene 
expression (Dorman, 2004), while others, like EspR, are critical in promoting virulence gene 
expression (Raghavan et al., 2008). Gene regulation by NAPs has been shown to occur, even 
for one protein, via a number of mechanisms. Fis has been shown to repress transcription both 
by binding at target promoters and occluding RNAP, as well as by preventing the isomerization 
of promoter open complexes (Schneider et al., 1999). IHF can function to promote the contacts 
between the αCTD of σ54-containing RNAP and target promoters (Macchi et al., 2003) and IHF 
can physically bend DNA to allow contact between other regulators and RNAP (Santero et al., 
1992). Additionally, the activity of specific transcription factors may be influenced by the 
presence of NAPs; the E. coli protein FNR is found to be limited to binding sites which are not 
occupied by H-NS, IHF, or Fis (Myers et al., 2013).  
Recent research into the structure of the bacterial chromosomes suggests that the 
overall organization of the chromosome may be dynamic, driven largely by supercoiling and the 
location of highly-expressed genes (Fisher et al., 2013; Le et al., 2013). Bacterial NAPs appear 
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to play a more significant role at a more local level of organization, in regions of less than 100 
kb in Caulobacter crescentus (Le et al., 2013). The protein abundance of many NAPs changes 
with growth state, so the nature of their association with DNA must change accordingly. 
Additionally, use of proteins such as Crp and Lrp in chromosomal organization would allow the 
dynamics of organization to change in response to nutritional cues.  
 
Chromatin immunoprecipitation followed by high-thoughput sequencing (ChIP-Seq) in 
bacteria 
 It is possible to identify all of the regions at which a given protein associates with the 
genome by performing chromatin immunoprecipitation followed by high-throughput sequencing, 
or ChIP-Seq. The first step of this process is to crosslink the protein-protein and protein-DNA 
complexes present in the cell; the crosslinking can be achieved by adding a crosslinking agent 
such as formaldehyde. The protein of interest is then specifically immunoprecipitated from cell 
lysates, isolating the protein-DNA interactions that were present at the time of crosslinking. The 
next steps are to purify the fragments of DNA that were isolated as a result of their association 
with the protein of interest, generate libraries of immunoprecipitated DNA for high-throughput 
sequencing, and sequence the DNA. Subsequent computational steps are aimed at identifying 
which regions of the genome are more frequently immunoprecipitated with the protein of interest 
than some background control. These steps include aligning the short sequenced DNA reads to 
the genome and determining criteria for significant enrichment of reads. Typically, a set fold-
enrichment of ChIP-Seq reads over background is used. Another criteria that is indicative of 
specific association between a protein and a region of DNA is sometimes referred to as positive 




Figure 1.4. Peak shift in ChIP-Seq data is indicative of protein association. The schematic diagram 
depicts the visualization of ChIP-Seq data from Fur (from this study; see Chapter 3). Genomic location is 
listed along the X-axis at the top, in both kb and locus number. Fragments of DNA associated with Fur 
protein from different cells are variable in length. Each DNA fragment will be sequenced from the 5′ end, 
resulting in local enrichment of strand-specific reads on either side of the Fur-binding site (red indicates 
sequencing from the plus strand, blue indicates sequencing from the minus strand). The overlapping red 
and blue bars indicate actual read data. The point of maximum read enrichment along each strand is 
identified and the maximum points for the two strands are merged midway, yielding a normalized peak 
representative of Fur association, depicted in purple. Figure adapted from Valouev et al., 2008. 
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 A peak shift is essentially an artifact that results from the association of a protein with a 
region of DNA. The protein of interest will have been associated with fragments of DNA of 
various sizes and the length of the sheared DNA on either side of the associated protein will be 
variable (Figure 1.3). In sequencing a large number of fragments, the location of the protein 
should average out to approximately the center of a given region with more reads than 
background. However, sequence data is always generated directionally, from the 5′ end to the 3′ 
end of DNA fragments. For bona fide regions of protein association, this will result in a large 
number of reads aligning to the positive strand upstream from the site of association and a large 
number of reads aligning to the negative strand downstream from the site of association (Figure 
1.3). Thus, the association of a protein with a single region of the DNA results in two strand-
specific peaks of enrichment. To more accurately represent the location of the DNA-associated 
protein, the two strand-specific peaks can be merged at the mid-way point between the two 
peaks. A positive peak shift refers to shifting these two peaks together in a manner that reflects 
association of a protein with the region of DNA (i.e., reads on the positive strand shifting 
downstream and reads on the negative strand shifting upstream; Figure 1.3). Negative peak 
shift, which would reflect an abundance of reads aligning to the negative strand followed by 
reads aligning to the positive strand, could not be generated by the immunoprecipitation of DNA 
between the two local peaks and so is indicative of artifactual enrichment.  
The use of ChIP-Seq has several advantages in comparison to the earlier-developed 
method of chromatin immunoprecipitation followed by the hybridization of immunoprecipitated 
DNA to a microarray, called either ChIP-chip or ChIP-on-chip (Park, 2009). When using ChIP-
Seq, direct sequencing of the immunoprecipitated DNA circumvents the need to design a high-
density microarray containing the entire genome sequence. And because the output signal no 
longer relies on hybridization of DNA to probes of pre-determined sizes, it is possible to obtain 
more accurate and more refined peak sizes. Additionally, the dynamic range of sequencing is 
much larger than the dynamic range of microarray technology, resulting in greater sensitivity.  
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The use of ChIP-Seq in bacterial studies as a method to identify locations of protein 
association within the genome has become common; while from 2009-2012, fewer than ten 
papers studying bacteria included ChIP-Seq analyses, at least thirteen papers used ChIP-Seq 
to study bacterial transcription factors in 2013. Published studies range from identification of the 
binding sites for a single transcription factor, to large-scale studies such as the work performed 
by the Galagan group, which has already assessed 50 transcription factors in M. tuberculosis by 
ChIP-Seq and aims to examine all of the M. tuberculosis transcription factors using this 
approach (Galagan et al., 2013a; 2013b).  
Several initial ChIP-Seq studies in bacteria have been performed on well-described 
NAPs (Galagan et al., 2013a; Kahramanoglou et al., 2011; Prieto et al., 2011; Wang et al., 
2013). The protein binding regions for proteins such as IHF, H-NS and Fis have been previously 
assessed by ChIP-chip (Castang et al., 2008; Cho et al., 2008; Grainger et al., 2006). However, 
comparison between datasets has demonstrated that ChIP-Seq results in significantly better 
resolution in terms of binding site identification (Kahramanoglou et al., 2011).  
 In studying proteins that have been considered canonical transcription factors (i.e., those 
that function by binding to specific sites present at the promoters of target genes to influence 
gene expression), an apparently frequent result is the identification of protein-association sites 
at non-canonical, that is, non-promoter, regions (Bush et al., 2013; Butcher et al., 2011; 
Jungwirth et al., 2013; Perkins et al., 2013; Scott et al., 2013; van Kessel et al., 2013). 
Occasionally, these regions are discarded from analyses (Bush et al., 2013; Perkins et al., 
2013; Scott et al., 2013). In some cases, the investigators choose to validate the unexpected 
association between the protein and DNA, as in the case of the transcription factor GlxR in 
Corynebacterium glutamicum; GlxR was found to bind a number of intragenic sequences, and 
one that was unlikely to be near a promoter was shown to bind purified GlxR by electrophoretic 
mobility shift assay (EMSA) (Jungwirth et al., 2013).  
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These apparently non-canonical binding sites need not necessarily be truly non-
canonical. Intragenic binding sites could be representative of unidentified promoters, be 
representative of alternative promoters, be representative of promoters for small RNA species, 
or reflect poor genome annotation and actually are within intergenic regions.  
Alternately, non-canonical binding sites could represent transcription factors functioning 
at sites distal to the regulated promoter. There are a number of examples of long-range 
interactions in prokaryotes, such as repression of the E. coli araBAD operon. The AraC protein 
binds a site over 200 base pairs from the araBAD promoter in order to repress transcription 
(reviewed in Schleif, 2003). However, while these long-range interactions are not artifacts and 
do affect the biology of the cell, it typically seems that increasing the distance between the 
regulator’s site of binding and the regulated promoter tends to result in a diminished regulatory 
effect. If the occupancy of non-canonical sites do have regulatory consequences, it is possible 
that the regulated promoter is distant and thus the effect of the regulator is slight, which could 
contribute to the reason these binding sites were not previously identified.  
Another explanation for proteins that associate with both canonical and non-canonical 
sites may be that they function analogously to the recently characterized EspR protein in M. 
tuberculosis. EspR was originally identified as a transcription factor necessary for promoting 
expression of genes at the espA locus, encoding a secretion system critical for virulence 
(Raghavan et al., 2008). More recently, EspR was found to both make long-range DNA looping 
interactions to directly promote espA expression, as well as play a role in organizing 
chromosome structure (Blasco et al., 2012; Hunt et al., 2012). This suggests that transcription 
factors may have multiple functions when associated with DNA, and the category of NAP may 
continue to expand. These newly classified NAP members may or may not be highly abundant 
and may function both as site-specific transcription factors and chromosomal organization 
modulators, rather than be highly abundant and associate with the entire chromosome.  
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Many ChIP-Seq studies in bacteria have also identified a large number of sites detected 
with low enrichment over background, or so called weak binding sites (Chumsakul et al., 2011; 
Galagan et al., 2013a; 2013b; Jungwirth et al., 2013). However, the extent to which a region is 
enriched by ChIP-Seq can be influenced by a large number of factors and does not necessarily 
correlate to binding strength. Additionally, choices regarding the significance or cut-off values for 
signal intensity are frequently based on arbitrarily chosen fold enrichments. Several studies 
suggest that widespread, apparent weak binding may not be entirely artifactual.  
Analysis of FNR binding sites across the E. coli genome identified significant variability 
in enrichment of ChIP-Seq peaks (Myers et al., 2013). The authors found that, under the 
conditions examined, the FNR binding sites with variable enrichment were saturated in vivo. By 
examining the relative enrichment of FNR binding sites with a range of induced FNR protein, it 
was determined that the variation in ChIP-Seq peak enrichment was likely due either to variable 
crosslinking efficiency or variable immunoprecipitation within given genomic contexts (Myers et 
al., 2013). These results highlight that comparing the relative enrichment of a particular factor at 
different locations may not be biologically relevant. 
Other studies of widespread identification of ChIP-Seq peaks with low enrichment 
suggest that protein abundance may be a key determinant in identifying regions of association 
for a particular factor. It logically follows that under conditions of low protein abundance, it will 
be harder to detect low-affinity binding sites. The detection of more putative protein binding sites 
in the presence of more protein has been reported in work performed in M. tuberculosis 
(Galagan et al., 2013a), suggesting that the sites of association for these factors are not 
saturated. It was found that increasing the abundance of the transcription factor of interest 
results in the identification of more peaks and, generally, with greater enrichment of the 
previously identified peaks (Galagan et al., 2013a). Additionally, genes associated with many of 
the weaker peaks have been found to be regulated by the transcription factor of interest, 
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suggesting that the peaks identified with weak enrichment may be biologically relevant (Galagan 
et al., 2013a).  
One way to circumvent the issue of protein abundance is to induce saturation of binding 
sites. Saturation of binding sites was the goal of Davies et al; in their work they overexpressed 
the Vibrio cholerae Fur protein in order to identify all possible binding sites (Davies et al., 2011). 
Using this strategy, known sites of Fur association were significantly increased and no false 
positives were reported. Many of these sites were linked to Fur regulation by RNA-Seq studies, 
and inspection of intragenic binding regions identified novel putative small RNAs under the 
control of Fur (Davies et al., 2011).  
 Another study provides an alternate suggestion for the function of sites with weak 
binding. In a paper demonstrating a novel approach to ChIP-Seq, Genome Footprinting by high-
throughput sequencing (GeF-Seq), essentially DNaseI footprinting in vivo followed by high-
throughput sequencing, the authors identify a specific bipartite binding motif for the transcription 
factor AbrB (Chumsakul et al., 2011). They had found a large number of weak binding sites, but 
based their analysis and motif identification on a subset which corresponded to the most 
enriched sites. Subsequently, they re-assessed the weaker sites for the AbrB bipartite motif and 
found that a single motif, rather than the bipartite motif, was enriched at the weaker sites. They 
suggest that the sites with weak affinity may be used to concentrate AbrB along the DNA to 
allow it to localize to high affinity sites (Chumsakul et al., 2011).  
 A significant strength of ChIP-Seq studies is their ability to identify regulatory networks, 
which would be difficult to discern using traditional transcriptomic approaches. By using ChIP-
Seq to identify the direct targets of a particular transcription factor, and coupling that information 
with transcriptomic analysis such as RNA-Seq, regulatory networks and hierarchies can be 
revealed. An example is that ChIP-Seq of a single transcription factor, such as ArcA in E. coli, 
reveals that ArcA is in the center of a significant regulatory network, regulating other 
transcription factors and thus both directly and indirectly affecting the expression of a wide 
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range of genes (Park et al., 2013). The information gleaned from the fifty transcription factors 
examined by ChIP-Seq in M. tuberculosis thus far is starting to elucidate the complex network of 





 F. tularensis is an important human pathogen which requires appropriate gene 
regulation for pathogenesis. While the transcription factors MglA, SspA, PigR, and PmrA, along 
with the small molecule (p)ppGpp are necessary for intramacrophage survival and virulence, 
there are many other transcription factors which contribute to regulating F. tularensis virulence. 
ChIP-Seq is a powerful tool that can be used to identify direct targets of transcription factors, as 
well as elucidate protein function and reveal regulatory networks.  
 In the following chapters, I report my studies aimed at finding the regions of the F. 
tularensis genome that are bound by those transcription factors implicated in controlling 
virulence. In doing so, I determine that MglA, SspA, and PigR are found at essentially all 
promoters, suggesting that PigR is not a site-specific DNA-binding protein that is only found at 
target promoters. I also identify differences in the regulatory activities of the MglA-SspA complex 
and PigR. I find that PmrA is likely to indirectly affect regulation of genes found on the FPI 
through its direct effect on the expression of the pigR. I additionally identify putative NAPs in F. 
tularensis, characterize regulons of all the virulence-associated transcription factors, and 
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Abstract 
 In Francisella tularensis, MglA, SspA, and PigR are transcription factors that are 
essential for the ability of the bacterium to replicate within macrophages. Previous work has 
established that MglA and SspA form a heteromeric complex that interacts with RNA 
polymerase (RNAP). An additional interaction between the MglA-SspA complex and PigR, a 
putative DNA-binding protein, is thought to be necessary to specifically promote expression of 
virulence genes. We determined those regions of the F. tularensis genome that associate with 
MglA, SspA, and PigR using ChIP-Seq and found that these three regulators are found at 
virtually all detected promoters. Moreover, we found that the ability of PigR to specifically 
associate with promoter regions was dependent upon MglA. We identified a potential 
mechanism for specificity involving a sequence motif in PigR-regulated promoters, which we 
have tentatively called the PigR response element (PRE).  Finally, although PigR, MglA, and 
SspA were thought to control the same set of genes, we have been able to discern a difference 
between the MglA/SspA and PigR regulons. Transcriptomic analyses suggest that PigR only 
acts as a positive regulator, while MglA appears to act both as a positive regulator in concert 
with PigR and a negative regulator independently of PigR, with MglA negatively regulating 
genes in the σ32 regulon. Together, our data lead to a model in which the MglA-SspA complex 
promotes formation of the σ70-containing RNAP holoenzyme and is found at all promoters, 
providing a point of contact between PigR and RNAP. In this model, PigR interacts with the 
RNAP-associated MglA-SspA complex at all promoters but only activates transcription from 
those that contain the PRE. 
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Introduction 
 Francisella tularensis is a Gram-negative bacterium and the etiological agent of 
tularemia. This intracellular pathogen causes disease in small rodents and can be transmitted 
by a wide variety of insect vectors (Petersen et al., 2009). Humans can become infected by F. 
tularensis in a variety of ways, including exposure to an infected animal or vector, exposure to 
contaminated food or water, or exposure to aerosolized bacteria (Tärnvik and Chu, 2007). 
Because the infectious dose is extremely low and because certain strains of F. tularensis cause 
disease with a high incidence of mortality, the organism is considered a potential bioweapon 
(Dennis et al., 2001). Understanding how these bacteria can infect the host, survive in the host 
environment, and replicate to continue the infection is thus of great importance and interest.  
Many studies and screens have been performed to identify factors critical to the 
virulence of F. tularensis. It has become clear that several transcription factors are critical for 
pathogenicity. MglA, a stringent starvation protein A (SspA) family member, was the first 
virulence factor demonstrated to be important for the intracellular survival and replication of F. 
tularensis (Baron and Nano, 1998). In E. coli, SspA is one of the most highly produced proteins 
during the stringent response and has been implicated in mediating the response to cellular 
stress (Ishihama and Saitoh, 1979; Williams et al., 1994). F. tularensis encodes one other SspA 
family member, named SspA, and both MglA and SspA have been found to be critical for 
virulence gene expression (Charity et al., 2007). It has been demonstrated that MglA and SspA 
form a heteromeric complex that interacts with RNA polymerase (RNAP). The MglA-SspA 
complex interacts with an additional protein called PigR in F. tularensis subsp. holarctica LVS 
(also known as FevR in F. tularensis subsp. novicida), to regulate a common set of genes 
(Brotcke and Monack, 2008; Charity et al., 2007; 2009). The shared regulon of MglA, SspA, and 
PigR encompasses approximately 100 genes, including those encoding known virulence factors 
as well as many whose products are not known to be linked to virulence (Brotcke and Monack, 
2008; Brotcke et al., 2006; Charity et al., 2007; 2009). It is notable that MglA, SspA, and PigR 
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are critical for expression of the genes found on the Francisella Pathogenicity Island (FPI), 
which encodes a type VI-like secretion system demonstrated to be indispensible for virulence 
(reviewed in Bröms et al., 2010).  
 Previous work performed in this laboratory led to a model for virulence gene regulation 
by MglA, SspA and PigR (Figure 2.1 and Charity et al., 2009). In this model, PigR, a putative 
DNA-binding protein, binds specifically to a DNA sequence present at the promoters of target 
genes. DNA-bound PigR functions as a transcription activator by contacting the RNAP-










Figure 2.1. A working model for how the MglA-SspA complex and PigR control a common set of 
genes. PigR, a putative site-specific DNA-binding protein, interacts directly with the RNAP-associated 
MglA-SspA complex and stabilizes the binding of RNAP at specific target promoters such as the iglA 







 The model specifies that PigR, like other classical transcription activators, is a site-
specific DNA-binding protein that only associates with the promoter regions of MglA/SspA/PigR 
regulated genes. This model also specifies that PigR interacts with the RNAP-associated MglA-
SspA complex at these specific target promoters; the MglA-SspA complex is therefore expected 
to be present at these target promoters. This model does not address whether the MglA-SspA 
complex might be found at other promoters whose activity is not regulated by PigR. 
Furthermore, although the model specifies that PigR interacts with the MglA-SspA complex that 
is associated with the RNAP holoenzyme during transcription initiation, it does not address 
whether the MglA-SspA complex is associated with the RNAP core enzyme during transcription 
elongation.  
 Using chromatin immunoprecipitation followed by high-throughput DNA sequencing 
(ChIP-Seq), we show that PigR, MglA, and SspA are present at virtually all detected promoters 
in F. tularensis.  We also demonstrate that PigR requires MglA (and thus presumably the MglA-
SspA complex) in order to specifically associate with promoters. Finally, we present evidence 
that the promoters of PigR-regulated genes contain a specific sequence motif. Our findings 
result in a revised model for the regulation of virulence gene expression in which PigR contacts 
the RNAP-associated MglA-SspA complex at all promoters. However, PigR may only function 
as an activator in concert with MglA and SspA at those promoters that contain a specific 
sequence motif. Transcriptomic analyses provide support for this model, as it was found that 
PigR, in concert with MglA, only appears to function as a positive regulator. MglA, on the other 
hand, appears to not only positively regulate a large number of genes in concert with PigR but 




Defining promoter regions in F. tularensis using ChIP-Seq 
In order to address the question of whether PigR specifically associates with target 
promoters, we first sought to define the locations of all promoters in F. tularensis. To do this, we 
determined the locations of the β′ subunit of RNA polymerase (RNAP) on the chromosome 
using ChIP-Seq. To facilitate the immunoprecipitation of the β′ subunit of RNAP, we constructed 
a strain of F. tularensis LVS in which the chromosomal copy of the rpoC gene (encoding β′) was 
modified to encode the β′ subunit with a vesicular stomatitis virus-glycoprotein (VSV-G) epitope 
tag fused to its C-terminus (Figure 2.2A). This results in cells which synthesize the β′ subunit of 
RNAP with a VSV-G tag at close to native levels (Figure 2.2B).  Because the β′ subunit is a core 
subunit of RNAP, it will be found at both promoter regions and within actively transcribed genes. 
Thus, enrichment of the β′ subunit within a particular region is not exclusively indicative of 
promoter location. In order to use the strain encoding the VSV-G tagged β′ protein to specifically 
identify promoter locations, we performed ChIP-Seq after treatment of the cells with the small 
molecule rifampicin (rif) to effectively trap RNAP at promoters (Campbell et al., 2001; Herring et 
al., 2005). By determining the location of the β′ RNAP subunit in cells treated with rif, we 






Figure 2.2. Schematic diagram for producing strains with epitope-tagged transcription factors. A. 
The integration vector contains a fragment of the rpoC gene (FTL_1743) followed by DNA specifying a 
VSV-G epitope tag. A single homologous recombination event produces a strain, LVS β′-V, that 
synthesizes the VSV-G tagged β′ subunit of RNAP (β′-V) from the native rpoC locus. B. The VSV-G 




chromosome rpoC chromosome 





 F. tularensis only encodes two σ factors: σ70, the so-called housekeeping σ factor, and 
σ32, the so-called heat-shock σ factor (Grall et al., 2009). As a complementary approach to 
identify promoters in F. tularensis, and to determine which promoters are σ70-dependent and 
which are controlled by σ32, we performed ChIP-Seq on both σ factors. We used the strategy 
used above to modify the chromosomal rpoD and rpoH genes, encoding σ70 and σ32 
respectively, to encode the corresponding RNAP subunit with a VSV-G epitope tag fused to its 
C-terminus. We also chose to similarly modify rho, the gene encoding the transcription 
termination factor Rho, as an example of a protein that associates with RNAP at non-promoter 
regions, and oxyR, which encodes the oxidative stress transcription regulator OxyR, as an 
example of a site-specific DNA-binding protein and transcription factor which exerts its 
regulatory effects largely at promoter regions. The regions identified by determining the location 
of σ70 overlapped the majority of the promoters that were identified by determining the location 
of the β′ RNAP subunit in cells grown in the presence of rif. However, under our growth 
conditions, only four regions were identified as enriched for σ32. By defining a promoter as a 
region with significant enrichment of either σ factor and/or the β′ subunit of RNAP in the 









Table 2.1. Promoter regions identified by ChIP-Seq 
Factor Peaks 
β′ + rif 526 
σ70 333 
σ32 4 




Figure 2.3 contains an example of a section of the genome with regions identified as 
enriched after ChIP-Seq of β′, β′+rif, σ70 and σ32. The β′ subunit of RNAP is found both at 
promoter regions and within actively transcribed genes. Determining the location of the β′ 
subunit of RNAP after rif treatment specifically identifies promoter regions, which correlate well 
to regions of σ factor enrichment. These data suggest that the region between FTL_1409 and 
FTL_1410 contains a σ70-dependent promoter, while the region between FTL_1410 and 
FTL_1411 contains a σ32-dependent promoter (Figure 2.3).  
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 Figure 2.3. Putative promoter regions are identified using ChIP-Seq. A representative section of the 
chromosome is depicted. Genomic position is indicated on the X-axis by F. tularensis LVS locus number; 
gray boxes represent genes, which are above the black line if they are encoded on the plus strand and 
below the black line if they are encoded on the minus strand. A representative track illustrating the density 
of normalized mapped sequencing reads is depicted on the Y-axis after ChIP-Seq of each factor, β′ 
(blue), β′+ rif (purple), σ70 (aqua), σ32 (green), and Rho (brown). Areas of significantly enriched reads, 
referred to here as peaks, are indicated by the horizontal gray boxes below the read density plot and sites 
of maximum enrichment are indicated by the red lines. Putative promoter regions, which are areas with 
significant enrichment of β′ + rif, σ32, or σ70 association with the chromosome, are indicated by the purple 
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MglA, SspA, and PigR are found at essentially all promoters in F. tularensis 
Having defined the location of putative promoter regions across the genome, we next 
determined at which promoters PigR, MglA, and SspA were located. We utilized a tagging 
strategy similar to the one used with the RNAP subunits, which allowed us to modify the 
chromosomal copy of each gene to encode a protein containing a C-terminal epitope tag. Cells 
from the resulting strains were used for ChIP-Seq to determine the chromosomal locations of 
PigR, MglA, and SspA. 
 These data revealed that PigR, MglA, and SspA are located specifically at promoters 
(i.e. they are not found to be enriched throughout the gene similarly to Rho), and at not only 
candidate MglA/SspA/PigR regulated promoters, but also at the majority of promoters 
throughout the genome. This is illustrated in Figure 2.4, which depicts the data from the iglA, 
proS and FTL_0651 promoter regions. Expression of the iglA gene is dependent on the 
presence of MglA, SspA, and PigR, whereas the expression of proS and FTL_0651 are not. In 
contrast, we did not identify enrichment of OxyR at either promoter, indicating that we are not 
simply immunoprecipitating all promoters with every transcription factor. The identification of 
PigR at essentially all promoters suggests that PigR is not a sequence-specific DNA-binding 





Figure 2.4. PigR and the MglA-SspA complex co-localize at the promoters of target and non-target 
genes. Representative sections of the chromosome are depicted, including promoter regions for both a 
target gene (FTL_0111, FPI virulence gene iglA, left) and non-target regions (FTL_0650, proS, encoding 
a tRNA synthase and FTL_0651, encoding a transposase). Genomic position is indicated on the X-axis 
by F. tularensis LVS locus number; gray boxes represent genes, which are above the black line if they 
are encoded on the plus strand and below the black line if they are encoded on the minus strand. A 
representative track illustrating the density of normalized mapped sequencing reads is depicted on the Y-
axis after ChIP-Seq of each factor, β′+ rif (purple), σ70 (aqua), MglA (green), PigR (orange), and OxyR 
(pink). Areas of significantly enriched reads, referred to here as peaks, are indicated by the horizontal 
gray boxes below the read density plot and sites of maximum enrichment are indicated by the red lines. 
Putative promoter regions, which are areas with significant enrichment of β′ + rif, σ32, or σ70 association 
with the chromosome, are indicated by the purple boxes above the gene annotations. The concordance 






































































The concordance among the localization of MglA, SspA, and PigR is further 
demonstrated in Figure 2.5. The Venn diagram in Figure 2.5 represents the 98% of promoter 
regions identified by ChIP-Seq of σ70 at which at least one of the three factors, MglA, SspA, or 
PigR, are found. The percentages in Figure 2.5 indicate the concordance of localization 
between MglA, SspA, and PigR at σ70-associated promoters. All three factors, MglA, SspA, and 









Figure 2.5. The MglA-SspA complex and PigR are present at the majority of promoters. The overlap 
between MglA, SspA, and PigR ChIP-Seq peaks at promoter regions identified by ChIP-Seq of σ70 is 
depicted (Venn diagram is not to scale). Diagram represents 326 of the 333 (i.e., 98%) ChIP-Seq peaks 
identified by σ70. 
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PigR requires MglA in order to specifically associate with promoters  
Since PigR was found together with MglA-SspA at the majority of promoters, and given 
that PigR may be a DNA-binding protein, it was unclear if PigR is found at all promoter regions 
regardless of the presence of the MglA-SspA complex, potentially binding a specific DNA 
sequence found at all promoters, or if PigR requires the presence of the MglA-SspA complex in 
order to associate with promoter regions. To determine if PigR requires the MglA-SspA complex 
to associate with promoter regions, we performed ChIP-Seq on PigR in the presence and 
absence of MglA. In particular, we performed ChIP-Seq with cells of the ∆pigR mutant strain 
and cells of the ∆mglA ∆pigR mutant strain in which we expressed the pigR gene modified to 
encode the PigR protein with a C-terminal VSV-G tag (pigR-V) from a plasmid under the control 
of a heterologous promoter. The protein encoded by pigR-V is functional, as it has been 
previously demonstrated to complement the ∆pigR mutant strain with respect to iglA transcript 
abundance (Charity et al., 2009). It was necessary to drive the expression of pigR-V from a 
heterologous promoter in these experiments because expression of the native pigR gene is 
dependent upon MglA (and SspA) (Brotcke et al., 2006; Charity et al., 2007). We assessed the 
abundance of the PigR-V protein in cells of the ∆pigR mutant and the ∆mglA ∆pigR mutant 
strains. While there was less PigR-V produced in the ∆mglA ∆pigR mutant strain, protein levels 







Figure 2.6. The abundance of ectopically produced PigR-V is similar in cells of the ∆pigR mutant 
strain and cells of the ∆mglA ∆pigR mutant strain. A Western blot analysis of the amount of 
ectopically produced PigR-V protein. Protein from equivalent amounts of cells from triplicate cultures of 
(lanes 1-3) LVS cells with the pF plasmid (an empty vector control), (lanes 4-6) LVS ∆pigR cells with the 
pF-PigR-V plasmid, and (lanes 7-9) LVS ∆pigR ∆mglA cells with the pF-PigR-V plasmid were 
electrophoresed on a 4-12% Bis-Tris NuPAGE gel and analyzed by Western blotting. Upper panel, 
immunoblot probed with anti-VSV-G. PigR-V is found in cells of the ∆pigR mutant and in cells of the 
∆mglA ∆pigR mutant at comparable levels. Lower panel, immunoblot probed with anti-GroEL. Detection 
















Comparison of the ChIP-Seq results obtained with ectopically produced PigR with those 
obtained with native PigR revealed that ectopic production of PigR does not significantly alter 
the location of this protein (Figure 2.7). Comparison of the ChIP-Seq results obtained with 
ectopically produced PigR in the presence and absence of MglA revealed a striking difference in 
location; we found no specific enrichment of PigR at promoter regions in the absence of MglA 
(Figure 2.7). This indicates that MglA, and by inference the MglA-SspA complex, is required for 
PigR to specifically associate with promoter regions. 







Figure 2.7. PigR requires MglA to specifically associate with promoter regions. Representative 
sections of the chromosome are depicted, including promoter regions for both a target gene (ilvE, 
FTL_0131, left) and non-target regions (FTL_1658, fimV, encoding a Type IV pilus assembly protein). 
Genomic position is indicated on the X-axis by F. tularensis LVS locus number; gray boxes represent 
genes, which are above the black line if they are encoded on the plus strand and below the black line if 
they are encoded on the minus strand. A representative track illustrating the density of normalized 
mapped sequencing reads is depicted on the Y-axis after ChIP-Seq of each factor, β′+ rif (purple), σ70 
(aqua), PigR (orange), ectopically expressed PigR from ∆pigR cells (pink), and ectopically expressed 
PigR from ∆pigR ∆mglA cells (yellow). Areas of significantly enriched reads, referred to here as peaks, 
are indicated by the horizontal gray boxes below the read density plot and sites of maximum enrichment 
are indicated by the red lines. Putative promoter regions, which are areas with significant enrichment of β′ 
+ rif, σ32, or σ70 association with the chromosome, are indicated by the purple boxes above the gene 
annotations. This region illustrates that enrichment of ectopically expressed PigR in a ∆pigR strain is 
similar to chromosomally encoded PigR. In comparison, there is a marked lack of promoter-specific 
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Cells lacking MglA or PigR have different growth rates 
Because MglA, SspA, and PigR appear to regulate the expression of the same set of 
genes, and because these three factors are present at virtually all promoters, we were 
interested in determining if cells lacking either MglA or PigR differed at all phenotypically. We 
observed, consistent with previously reported findings, that cells of the LVS ∆mglA mutant strain 
exhibit a slow growth phenotype (Figure 2.8; Charity et al., 2007; Honn et al., 2012). However, 
we found that a strain with a deletion of pigR does not have a significantly altered growth rate 
(Figure 2.8). We found the doubling times of cells of the wild-type strain, cells of the ∆pigR 
strain, and cells of the ∆mglA strain during log phase to be approximately 159, 156, and 203 
minutes, respectively. This is a surprising result, if the only functions of PigR and MglA are to 
regulate exactly the same set of genes. These data indicate that there are differences between 






Figure 2.8. Cells of the ∆pigR mutant strain grow similarly to wild-type cells whereas cells of the 
∆mglA mutant strain grow more slowly than wild-type cells. Each dot represents the average OD600 
value of three cultures at the indicated time point, grown in supplemented Mueller-Hinton broth, with 
standard deviations marked. 
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PigR and MglA positively regulate the expression of the same set of genes 
Using ChIP-Seq we found MglA, SspA, and PigR present at virtually all promoter 
regions. Additionally, previous studies found that in F. tularensis there is significant overlap in 
the genes regulated by MglA, SspA, and PigR (Brotcke and Monack, 2008; Charity et al., 2009). 
Yet the loss of MglA results in a slow growth phenotype while the loss of PigR does not. We 
reasoned that this might be the result of differences between the genes that MglA and PigR 
regulate. 
We asked if we could detect any differences between the regulons of MglA and PigR 
using an accurate and sensitive method. We utilized Nanostring to examine 100 transcripts, 19 
from genes previously shown to be positively regulated by MglA/SspA, 21 genes reported as 
negatively regulated by MglA/SspA, and 60 genes which have not been previously reported to 
be MglA/SspA regulated (Brotcke et al., 2006; Charity et al., 2007; Geiss et al., 2008). We 
compared the abundance of the described transcripts in wild-type cells to that in cells lacking 
either MglA or PigR. The results confirmed the positive regulation of 13 genes by both MglA and 
PigR (Table 2.2). Of the previously reported positively controlled genes, transcript levels of two 
were too variable to be significant and transcript levels of four others were found to be 











Gene Product MglA/SspA 
regulated1 
FTL_0449 pigR -27.6 NA** PigR transcription factor + 
FTL_0111 iglA -26.9 -23.9 Intracellular growth locus, subunit A  + 
FTL_0026 - -25.5 -19.1 3-hydroxyisobutyrate dehydrogenase  + 
FTL_0113 iglC -14.1 -10.6 Intracellular growth locus, subunit C  + 
FTL_1219 - -10.6 -4.9 Hypothetical protein + 
FTL_0126 pdpA -9.0 -14.7 Hypothetical protein + 
FTL_1218 - -7.7 -5.9 Hypothetical protein + 
FTL_0116 pdpC -5.8 -7.9 Hypothetical protein + 
FTL_0879 bla -5.0 -4.5 beta-lactamase + 
FTL_1790 ampG -4.7 -2.6 major facilitator superfamily protein + 
FTL_0125 pdpB -4.4 -8.5 Hypothetical protein + 
FTL_0500 speE -4.2 -2.0 Spermidine synthase + 
FTL_0491 - -4.1 -4.3 Outer membrane lipoprotein + 
FTL_0617 bfr -2.5 -1.3* bacterioferritin + 
FTL_0477 gcvT -2.3 -1.2 glycine cleavage system 
aminomethyltransferase T 
+ 
FTL_0068 gmhA -2.3 -1.1* phosphoheptose isomerase ND 
FTL_1731 - -2.2 -1.0* licB-like transmembrane protein ND 
FTL_0133 feoB -2.2 -1.3 ferrous iron transport protein ND 
FTL_0317 - -2.1 1.1 Hypothetical protein ND 
FTL_1727 ampD -2.1 -1.6 N-acetyl-anhydromuranmyl-L-alanine 
amidase 
ND 
FTL_1756 glpA -2.0 -1.6 anaerobic glycerol-3-phosphate 
dehydrogenase 
ND 
FTL_0646 - -1.9 -3.7 Hypothetical protein - 
FTL_1678 - -1.8 -3.0 conserved membrane hypothetical protein + 
FTL_0131 ilvE -1.5 -2.0 branched-chain amino acid aminotransferase 
protein (class IV) 
+ 
FTL_0388 - -1.3 -2.0 cation transporter ND 
1 “+”, gene previously described as positively regulated; “-”, gene previously described as negatively 
regulated; “ND”, gene not previously described as MglA/SspA regulated.  
* Not significant, T-test between deletion strain and wild-type LVS results in a p-value > 0.05. 
** Not applicable, no detectable pigR transcript in the ∆pigR mutant strain. 
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A significant difference between previous reports and these results is the presence of six 
additional genes, not previously reported as MglA-regulated, which have transcripts reduced 
more than 2-fold in the ∆mglA strain. While MglA is thought to regulate the expression of over 
100 genes, none of these genes have previously been reported to be under the control of MglA. 
They are all closer to the lower limit of the significance threshold than any of the previously 
reported transcripts. This suggests, not surprisingly, both that the Nanostring assay is likely 
more sensitive than the previous microarray analyses and, if this subset of genes is 
representative of the rest of the genome, that MglA could be affecting the expression of many 
more genes than previously thought.  
We found that the PigR regulon differed significantly from the MglA regulon in one 
principal way. Specifically, no transcripts were identified as being negatively regulated by PigR, 
in contrast to the 15 transcripts negatively regulated by MglA (Table 2.3). This indicates PigR 
appears to positively regulate the expression of most of the genes that are positively regulated 
by MglA but does not influence the expression of those genes that are negatively regulated by 
MglA. 















FTL_1265 folK 3.6 -1.5* 2-amino-4-hydroxy-6-
hydroxymethyldihydropteridine 
pyrophosphokinase/ 
dihydropteroate synthase  
ND + 
FTL_1600 ansB 2.9 -1.3* Periplasmic L-asparaginase II 
precursor 
- + 
FTL_1103 - 2.7 -1.2* DNA helicase, pseudogene - - 
FTL_1273 bioF 2.7 -1.2 8-amino-7-oxononanoate 
synthase 
- - 
FTL_1050 rpoD 2.7 -1.1* RNA polymerase sigma-70 factor - - 
FTL_0528 - 2.7 1.1* Type III restriction enzyme - - 
FTL_0450 psd 2.6 -1.0* phosphatidylserine 
decarboxylase 
- - 
FTL_0056 - 2.4 -1.4* NADH dehydrogenase - - 
FTL_1190 grpE 2.3 -2.8* heat shock protein GrpE - + 
FTL_1715 groE
S 
2.3 -2.7* co-chaperonin GroES  ND + 
FTL_1421 - 2.2 1.0* haloacid dehalogenase-like 
hydrolase family protein 
- - 
FTL_1948 - 2.2 -1.3 Major facilitator superfamily 
(MFS) transport protein 
- - 
FTL_1449 rnd 2.0 1.0* ribonuclease D - - 
FTL_1266 - 2.0 -1.5 lipase/esterase ND + 
FTL_0660 feoA 2.0 1.2 ferrous iron transport protein A ND - 
 1 “+”, gene previously described as positively regulated; “-”, gene previously described as negatively 
regulated; “ND”, gene not previously described as MglA/SspA regulated.  
2“+”, gene is part of the putative σ32 regulon; “-”, gene is not part of the putative σ32 regulon; as determined 
by this study and Grall et al., 2009. 
* Not significant, T-test between deletion strain and wild-type LVS results in a p-value > 0.05. 
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The putative σ32 regulon is comprised of genes whose transcripts are reported to be 
significantly upregulated upon heat-shock or overexpression of σ32 (Grall et al., 2009), and/or 
have translational start sites within either 100 bp upstream or 1 kb downstream from the 
maximal point of a σ32 ChIP-Seq peak. Many of the genes negatively regulated by MglA belong 
to this putative σ32 regulon. Direct comparison between cells lacking MglA and cells lacking 
PigR highlights that a significant difference between the two strains is the increased abundance 
of σ32-dependent transcripts in cells lacking MglA (Table 2.4). Higher levels of σ32-regulated 
transcripts in cells lacking MglA are consistent with the negative regulation of σ32-regulated 















FTL_1190 grpE -6.5 heat shock protein GrpE - + 
FTL_1715 groES -6.3 co-chaperonin GroES  ND + 
FTL_1265 folK -5.3 2-amino-4-hydroxy-6-
hydroxymethyldihydropteridine 
pyrophosphokinase/dihydropteroate synthase  
ND + 
FTL_1600 ansB -3.8 Periplasmic L-asparaginase II precursor - + 
FTL_0281 hsp40 -3.7 heat shock protein, hsp40  ND + 
FTL_1103 - -3.3 DNA helicase, pseudogene - - 
FTL_0056 - -3.3 NADH dehydrogenase - - 
FTL_1273 bioF -3.2 8-amino-7-oxononanoate synthase - - 
FTL_1266 - -3.1 lipase/esterase ND + 
FTL_1050 rpoD -2.8 RNA polymerase sigma-70 factor - - 
FTL_1948 - -2.8 Major facilitator superfamily (MFS) transport 
protein 
- - 
FTL_1372 - -2.8 lipoprotein ND - 
FTL_0450 psd -2.6 phosphatidylserine decarboxylase - - 
FTL_0528 - -2.4 Type III restriction enzyme - - 
FTL_0178 yidC -2.2 inner-membrane protein - - 
FTL_1421 - -2.2 haloacid dehalogenase-like hydrolase family 
protein 
- - 
FTL_0892 clpP -2.1 ATP-dependent Clp protease proteolytic subunit  ND + 
FTL_0283 - -2.1 aromatic amino acid HAAP transporter ND - 
1 “+”, gene previously described as positively regulated; “-”, gene previously described as negatively 
regulated; “ND”, gene not previously described as MglA/SspA regulated.  
2“+”, gene is part of the putative σ32 regulon; “-”, gene is not part of the putative σ32 regulon; as determined 
by this study and Grall et al., 2009. 
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Our findings suggest that MglA and PigR differ in their functions, such that PigR works in 
concert with MglA (and, by inference, SspA) to positively control gene expression, while MglA 
(and SspA) also negatively effects the expression of certain genes. Specifically, one function of 
the MglA-SspA complex may be to repress the expression of σ32-regulated genes. 
 
A specific sequence motif is found at the promoters of MglA/SspA/PigR-regulated genes 
While PigR is present at virtually all identified promoters, it appears to only promote the 
expression of a fraction of the corresponding genes. We hypothesized that while PigR is present 
at all promoters, PigR may only promote gene expression at specific promoters upon 
recognition of a specific sequence element. Using MEME, we searched for a motif in the 
promoter regions of genes that matched certain criteria (Bailey and Elkan, 1994). Specifically, 
genes must have been previously reported as PigR regulated in LVS (Charity et al., 2009) or 
demonstrated to be PigR-regulated in our Nanostring studies and have a PigR-promoter peak 
(as determined by our ChIP-Seq studies) upstream from the translation start site. Eleven genes 
fit our criteria and a 7 bp motif was found to be present in all 11 of the promoter regions 
analyzed (Figure 2.9A). A logo representing the 7 bp motif can be seen in Figure 2.9C. The 
transcription start site of 5 PigR-regulated genes has been identified and this motif maps to the 
same site relative to the transcription start site in all these regions, 6-8 bp upstream from the 
predicted -35 element (Figure 2.9B). We compared this region in PigR-regulated promoters to 
the same region in promoters mapped by Zaide et al., none of which appear to be regulated by 
PigR; the 7 bp motif was not found at these non-PigR regulated promoters (Zaide et al., 2011) 
(Figure 2.9B). This suggests that the motif is specific to PigR-regulated promoters, raising the 
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Discussion 
We have shown that MglA, SspA, and PigR are found at virtually all promoter regions in 
LVS, and that the association of PigR with promoters is dependent upon the presence of MglA. 
Furthermore, we have identified a sequence motif present upstream of the -35 element of 
promoters that may make them responsive to PigR. In addition, we identified differences 
between the functions of PigR and MglA. Specifically, MglA appears to function as both a 
positive and negative regulator and provides a function that maintains the normal growth rate of 
the cell. PigR appears to only act as a positive regulator of gene expression, only influencing the 
expression of those genes that are positively regulated by MglA and SspA.  
Finding PigR, MglA, and SspA at virtually all promoters suggests that these proteins are 
associated with the RNAP holoenzyme at all promoters. There is at least one other transcription 
regulator studied in other organisms that is also found at virtually all promoters. CarD is an 
essential transcription factor in Mycobacterium tuberculosis which directly interacts with RNAP 
to simulate transcription initiation (Srivastava et al., 2013). While PigR, MglA, and SspA are not 
essential transcription factors and are not thought to be homologous to CarD, it is possible that 
they function in an analogous manner.  
Consistent with the idea that a heteromer of MglA and SspA interacts with the σ70-
containing RNAP holoenzyme, σ70 together with the core subunits of RNAP and SspA were 
found to co-purify with MglA in LVS in stoichiometric amounts (Charity et al., 2007). There is 
also evidence that the SspA homodimer in E. coli promotes gene expression from specific 
promoters when associated with a site-specific DNA-binding protein, Lpa, and σ70-containing 
RNAP holoenzyme, but not the RNAP core enzyme or RNAP holoenzyme containing the 
alternate sigma factor, σS (Hansen et al., 2003).  
Both MglA and SspA lack any obvious DNA-binding motifs, and the crystal structure of 
the SspA homodimer from Yersina pestis lacks any obvious DNA-binding determinant (Hansen 
et al., 2005). Additionally, the E. coli SspA homolog was found to activate transcription from the 
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bacteriophage P1 late promoter Ps, but not bind to the promoter DNA (Hansen et al., 2003). 
Thus, there is no indication that the MglA-SspA complex would necessarily bind DNA directly to 
affect transcription.  
PigR requires the MglA-SspA complex in order to specifically localize to promoter 
regions. We infer from this that interaction between PigR and the RNAP-associated MglA-SspA 
complex directs PigR specifically to promoter regions. These findings do not rule out the 
possibility that PigR may also function through interaction with the DNA. 
We have identified a sequence motif present upstream of the -35 element of promoters 
that are positively regulated by PigR (and the MglA-SspA complex). This motif is found 6-8 bp 
from the predicted -35 element in PigR-responsive promoters. It should be noted that the 
distance between the -35 element and this motif may actually be a specific number of bp (i.e., 
either 6 or 7 or 8 bp), and that the variation in location relative to the -35 element could reflect a 
misannotation of the -35 element.  
Because the conserved motif in PigR-regulated promoters has the potential to confer 
responsiveness to PigR, we tentatively name it the PigR response element (PRE). It should be 
stressed that further experimentation is required to determine whether or not this motif truly 
represents a PRE.  Nevertheless, the identification of a motif associated with PigR-regulated 
promoters suggests that PigR may specifically recognize this motif and function to activate 
those promoters containing this motif by making simultaneous contacts with the DNA and with 
the RNAP-associated MglA-SspA complex. The fact that PigR is present at many promoters 
that are not positively regulated by PigR raises the possibility that at most promoter regions, 
PigR may bind the DNA in a non-sequence specific manner or may not bind the DNA at all.  
Although PigR contains a putative helix-turn-helix motif, PigR has yet to be shown to be 
capable of binding DNA. However, the PRE need not be bound by PigR directly. Association of 
PigR with the MglA-SspA-RNAP complex may allow contact between the PRE and part of 
RNAP, such as the α subunit C-terminal domain (αCTD), or even the MglA-SspA complex, 
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although there is a lack of evidence to suggest that the MglA-SspA complex could bind DNA. It 
is also possible that PigR might exert effects at some promoters that lack a PRE by contacting 
the DNA in a non-sequence specific fashion. Indeed, although the αCTD has been shown to 
bind specifically to the DNA at so-called UP-elements, non-sequence specific binding of the 
αCTD to the DNA has been shown to influence the activity of several promoters (Ross and 
Gourse, 2005). It will therefore be important to determine whether all PigR-controlled promoters 
contain a recognizable PRE.   
While PigR was previously thought to control the exact same set of genes as MglA and 
SspA (Brotcke and Monack, 2008; Charity et al., 2009), we found an important difference 
between the PigR and MglA/SspA regulons. In particular, using Nanostring, which is a sensitive 
method of detecting and quantifying RNA transcript abundance, we found that PigR positively 
regulates the expression of genes that are positively regulated by MglA/SspA but does not 
negatively regulate the expression of those genes that are negatively regulated by MglA/SspA.  
Intriguingly, many of the genes that have been found to be negatively regulated by MglA 
appear to be driven by σ32-dependent promoters. We offer a possible explanation for this 
finding.  We hypothesize that the MglA-SspA complex promotes formation of the σ70-containing 
RNAP holoenzyme but not the σ32-containing holoenzyme. This would be consistent with (i) our 
transcriptomic data demonstrating that σ32-regulated transcripts are more abundant in the 
absence of MglA (Tables 2.2 and 2.3), with (ii) the finding that MglA co-purifies with σ70 and with 
(iii) the idea that other members of the SspA family of proteins appear to specifically associate 
with σ70-containing RNAP holoenzyme (De Reuse and Taha, 1997; Hansen et al., 2003; Yin et 
al., 2013). In the absence of MglA a smaller fraction of the available RNAP core enzyme would 
be associated with σ70, allowing for an increase in the amount of σ32-containing RNAP 
holoenzyme in the cell and upregulation of σ32-controlled genes. MglA may therefore exert some 
of its negative effects on gene expression by influencing the competition between the two 
available σ factors in the cell. Crl, a transcription factor in E. coli, promotes σ38 activity by 
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promoting formation of the σ38-containing RNAP holoenzyme, and provides a precedent in the 
literature for a protein that promotes the formation of a specific holoenzyme species (Banta et 
al., 2013; Gaal et al., 2006; Pratt and Silhavy, 1998). Note that although it is formally possible 
that some of the effects of MglA on gene expression might be accounted for by the effects of 
MglA on cell growth, a mutant containing a transposon insertion in the FTL_0951 locus, which 
grows more poorly than a mglA mutant, did not exhibit increased expression of σ32-regulated 
genes (Charity et al., 2007).  
It is unclear to what extent MglA and SspA might influence the expression of σ70-
dependent genes by promoting the formation of the σ70-containing RNAP holoenzyme. 
Regardless of whether or not the MglA-SspA complex specifically promotes formation of the σ70-
containing RNAP holoenzyme, the principal role of the MglA-SspA complex in F. tularensis with 
respect to virulence gene expression appears to be to provide a point of contact between PigR 
and RNAP. Consistent with this notion, PigR and MglA appear to be equally important for 
intracellular growth. Strains lacking either protein are equally defective for intramacrophage 
growth and for virulence in a mouse model of infection (Brotcke and Monack, 2008; Charity et 
al., 2009).  
Our findings concerning the locations of PigR, MglA, and SspA together with our 
identification of a possible PRE have lead to a revised working model for how PigR works in 
concert with the MglA-SspA complex to positively regulate the expression of a specific set of 
genes. According to this model, PigR is associated with all σ70-dependent promoters through its 
interaction with the RNAP-associated MglA-SspA complex. However, only at those promoters 
that contain a PRE does PigR make sufficiently strong contact with the DNA to further stabilize 
the binding of RNAP and activate transcription.  
 While our current working model for how PigR works in concert with the MglA-SspA 
complex (Figure 2.10) is consistent with our data thus far, much work remains to both test and 
clarify it. Our future work will include explicitly testing whether the PRE renders a promoter 
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responsive to PigR, determining whether PigR is a DNA-binding protein, and determining 







Figure 2.10. A revised working model for how the MglA-SspA complex and PigR control a 
common set of genes. A. At promoters not regulated by MglA, SspA, and PigR, the three factors are 
found at promoter regions through their interactions with each other and RNAP. B. At promoters 
regulated by MglA, SspA, and PigR such as the iglA promoter, PigR specifically recognizes DNA 
containing the PigR responsive element (PRE), interacts directly with the RNAP-associated MglA-SspA 




Materials and Methods 
Plasmids, strains, and growth conditions 
 F. tularensis subsp. holarctica LVS was grown at 37°C in either Mueller Hinton (MH) 
broth (Difco), supplemented with glucose (0.1%), ferric pyrophosphate (0.025%), and Isovitalex 
(2%), or on cysteine heart agar (Difco) medium supplemented with 1% hemoglobin solution 
(VWR); when appropriate, kanamycin was used for selection at 5 µg/ml. E. coli strain XL1-blue 
(Stratagene) was used for plasmid construction and, when appropriate, kanamycin was used to 
select for resistance at 50 µg/ml.  
 
Integration vectors 
A modified version of pEX18Kan (provided by Shite Sebastian and Simon Dillon, 
Harvard Medical School, Boston, Massachusetts, United States) was used as the vector for 
integration constructs. We have used pEX18Kan for deletion constructs (Charity et al., 2007; 
2009); it utilizes a ColE1 origin of replication, which is nonfunctional in LVS, and contains the 
T903 kanamycin resistance gene (Epicentre) driven by the LVS groEL promoter. The plasmid 
pKL01 was generated by first amplifying the last 400 base pairs (bp) of the FTL_1743 locus 
(rpoC), minus the stop codon, by PCR. The 5′ primer contained DNA specifying a KpnI site 
upstream of the gene fragment. The 3’ primer included DNA containing a NotI site and one extra 
base pair, encoding a 3 amino acid alanine linker. The linker is followed by DNA specifying the 
11 amino acid vesicular stomatitis virus-glycoprotein (VSV-G) tag, followed by a stop codon and 
DNA specifying an EcoRI site. The corresponding PCR product was digested with KpnI and 
EcoRI and cloned into pEX18Kan that had been digested with KpnI and EcoRI, generating 
pKL01. We largely removed the sacB gene by digesting with MscI and EcoRV and re-ligating 
the vector together, resulting in pKL02. 
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Integration constructs for the remaining loci were generated by amplifying the last 250-
400 bp (depending on gene size) of the gene using a 5′ primer containing a KpnI site and a 3′ 
primer containing a NotI site, which allows each fragment to be fused with DNA specifying the 
alanine linker and VSV-G epitope tag. Fragments were subcloned into pKL02 that had been 
digested with KpnI and NotI. An alternate integration plasmid was generated for genes whose 
putative operons would potentially be interrupted by plasmid integration. To do this, another 
groES promoter was amplified from LVS genomic DNA and cloned upstream of the gene 
fragment, into the BamHI and PstI sites of the vector derived from pKL02, to drive expression of 
downstream genes. This alternate integration construct was necessary in adding an epitope tag 
to the sspA gene. We did not successfully ChIP-Seq MglA-VSV-G, and used the LVS strain 
expressing MglA with a C-terminal TAP tag at native levels, described previously (Charity et al., 
2007).   
 
Strain construction 
 Electroporation of integration plasmids into LVS was performed as described in Maier et 
al., 2004. Cells in which a single homologous recombination event had occurred between the 
integration vector and the chromosome were selected on cysteine heart agar with 1% 
hemoglobin and 5 µg/ml kanamycin. Strains containing the correct integration were confirmed 
by colony PCR, by Western blotting and/or Southern blotting.  
 
Southern blotting 
 Southern blots were largely performed as described in the Roche DIG protocols. Probes 
were synthesized using the PCR DIG Probe Synthesis Kit (Roche). For probes with AT-content 
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higher than 63%, amplified unlabeled probe was used as template for the probe labeling 
reaction and half the specified DIG dNTPs were used, supplemented with additional dATP and 
dTTP (for a final concentration of 100 µM dCTP and dGTP, 300 µM dATP, 265 µM dTTP, and 
35 µM DIG-11-dUTP).  
2.5 ug of genomic DNA was digested for 1 hour and separated on a 1% agrarose gel. 
The gel was incubated in 0.25 M HCl for 7 minutes, washed twice with deionized water, and 
incubated in Denaturation Solution (1.5 M NaCl, 0.5 M NaOH) twice for 20 minutes. DNA was 
transferred overnight to positively charged nylon membrane by capillary action and crosslinked 
to the membrane. Membranes were incubated in UltraHyb (Ambion) at the appropriate 
hybridization temperature for 1 hour prior to overnight hybridization at the same temperature in 
UltraHyb containing the appropriate probe. After hybridization, membranes were washed twice 
for 5 minutes in Low Stringency Buffer (2x SSC, 0.1% SDS) and twice for 15 minutes at 65°C in 
High Stringency Buffer (0.5x SSC, 0.1% SDS). The DIG Wash and Block Buffer Set (Roche) 
was used according to instructions to detect the DIG-labeled probe using CDP-Star (Roche).  
Ectopic PigR expression 
 Plasmids pF and pF-PigR-V (described previously, Charity et al., 2007) were used as a 
negative control vector and to drive ectopic expression of PigR with a C-terminal VSV-G tag, 
respectively. The pF-PigR-V plasmid contains DNA encoding the PigR protein fused to the VSV-
G epitope, which is driven from the groES promoter; the pF plasmid does not contain the pigR 
gene or DNA encoding the VSV-G epitope tag. These plasmids were electroporated into either 
the previously described LVS ∆pigR mutant strain (Charity et al., 2009), or  a LVS ∆pigR ∆mglA 
mutant strain, which was created by using the pEX2-∆mglA vector (Charity et al., 2007) in the 
∆pigR background, by allelic exchange and confirmed by Southern blotting.  
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Chromatin Immunoprecipitation (ChIP) 
 Cells were grown at 37°C in 100 mL of supplemented MH to mid-log (OD600 0.3-0.4), and 
when indicated, rifampicin (Sigma) was added to a final concentration of 50 µg/mL for 30 
minutes before crosslinking. Cells were incubated in a final concentration of 1% formaldeyhyde 
(Sigma) for 30 minutes to crosslink, after which glycine (Sigma) was added to a final 
concentration of 250 mM. ChIP was performed in biological triplicate (excepting β′ + rifampicin, 
OxyR, and ∆pigR pF-PigR-V, which were performed in duplicate, and σ70 which was performed 
in quadruplicate) with either 40 mL or 80 mL of culture using anti-VSV-G agarose beads (Sigma, 
catalog no. A1970) for cells synthesizing VSV-G tagged transcription factors or IgG Sepharose 
beads (GE Healthcare, catalog no. 17-0969-01) for cells synthesizing TAP-tagged transcription 
factors essentially as described previously (Castang et al., 2008), except that a water bath 
sonicator (Biorupter, Diagenode) was used to lyse cells and shear chromosomal DNA to 200 to 
500 bp. Immunoprecipitated DNA was quantified using the Quant-iT™ PicoGreen® dsDNA 
Assay Kit (Invitrogen). The same protocol was performed with the untagged LVS strain as a 
mock immunoprecipitation (mock IP) control. 
  
Illumina Library Preparation 
 Libraries were constructed with approximately 2 to 160 ng immunoprecipitated DNA 
using the TruSeq DNA Sample Prep Kit (Illumina, catalog no. FC-121-2002), generally following 
the supplied protocol; adapters were diluted 1:10 before ligation and libraries were gel-purified 
after 11 cycles of amplification. Libraries were quantified using the Quant-iT™ PicoGreen® 
dsDNA Assay Kit (Life Technologies) and sequenced by Elim Biopharmaceuticals, Inc. 
(Hayward, CA), using an Illumina Genome Analyzer Ilx generating 36 bp single-end reads.  
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ChIP-Seq data analysis 
 For each strain, the 36 bp reads were mapped to the F. tularensis subsp. holarctica LVS 
genome (NCBI locus AM233362) and the sequence of the integrated plasmid, if applicable, 
using bowtie2-2.0.6 (Langmead and Salzberg, 2012), allowing up to one mismatch. Regions of 
enrichment were called using QuEST, version 2.42 (Valouev et al., 2008). The three mock IP 
biological replicates, consisting of approximately 30.6 million reads, were merged and used as a 
background control for each biological replicate. Peaks in each biological replicate are regions 
that fit the following criteria: they are 1.5-fold enriched for reads over background, with a positive 
peak shift and strand correlation, and a q-value of less than 0.01. Peaks for each 
immunoprecipitated protein were defined as the maximal region identified in at least two 
biological replicates. Tracks were visualized using the Integrative Genomics Viewer (IGV), 
version 2.3 (Thorvaldsdóttir et al., 2013). Peak analyses were carried out using Perl scripts and 
BEDtools (Quinlan and Hall, 2010).  
 
Immunoblots 
 Cell lysates were separated by SDS-PAGE on 4-12% or 12% Bis-Tris NuPAGE gels in 
MES or MOPS running buffer (Life Technologies). Either the iBlot dry blotting system or the 
XCell II Blot Module (Life Technologies) was used to transfer proteins to either PVDF or 
nitrocellulose. Membranes were blocked with SuperBlock Blocking Buffer (Pierce) with 0.25% 
Surfact-Amps 20 (Pierce) for 1 hour to overnight. Membranes were then probed with polyclonal 
anti-VSV-G (Sigma) or anti-GroEL (provided by Karsten Hazlett, Albany Medical College, 
Albany, New York, United States) for one hour, washed (10 minutes incubations in TBST plus 
0.25% Surfact-Amps 20, 4 times) and re-blocked for 1 hour. After membranes were incubated 
with polyclonal goat anti-rabbit and washed, proteins were detected using SuperSignal West 
Pico Chemiluminescent Substrate or SuperSignal West Femto Chemiluminescent Substrate 
(Pierce).  
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 Transcriptomic Analysis 
 Cells of LVS, LVS ∆mglA (described in Charity et al., 2007), and LVS ∆pigR (described 
in Charity et al., 2009) were grown to mid-log in biological triplicate. 1 mL of each sample was 
pelleted (20,000 rcf for 5 minutes), resuspended in 500 µL Qiagen buffer RLT, frozen on dry ice 
and stored at -80°C. Equal amounts of lysate, normalized to OD600, in 4 µL Qiagen buffer RLT 
and 1 µL water were submitted to the Epithelial Cell Biology Core Facility (Boston Children’s 
Hospital) for processing using the Nanostring nCounter Prep Station and Digital Analyzer 
according to the manufacture’s instructions. Total transcript counts were normalized using 
internal controls with background subtraction. Transcript abundance was determined by 
averaging biological triplicates. Criteria indicating significant change in gene expression are a 2-
fold change in transcript abundance and P < 0.05 in a two-tailed Student’s t-test.  
 
Identifying a potential PRE by MEME 
 Genes with significant changes in expression in LVS ∆pigR in comparison to LVS from 
either this work (Table 2.2) or Charity et al., 2009 were examined for promoter regions with 
detectable PigR, identifying 11 genes (FTL_0026, FTL_0111, FTL_0126, FTL_0131, FTL_0207, 
FTL_0449, FTL_0491, FTL_1218, FTL_1219, FTL_1678, FTL_1790). The 400 bp region 
surrounding the maximal PigR binding site, upstream from 11 genes, excluding coding regions, 
was searched for a common motif using MEME (Bailey and Elkan, 1994).  
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Abstract 
 Studies of Francisella tularensis virulence regulation have focused on a few transcription 
regulators critical for intracellular survival. Yet many other transcription regulators have been 
identified as virulence factors and very little is known about how they function to promote 
pathogenesis. In this study, we identify the locations on the genome at which thirty F. tularensis 
transcription factors are found, including all of those previously implicated in the control of 
virulence. For each factor, we have described a putative regulon, and, in the case of OxyR and 
the LysR-type transcription regulator FTL_0040, we have determined which regulon members 
have previously been implicated in virulence. We did not detect PmrA, a transcription factor 
demonstrated to promote expression of genes on the Francisella Pathogenicity Island (FPI), at 
critical FPI promoters. We suggest that PmrA may be indirectly influencing the expression of 
FPI genes by directly controlling the expression of another factor known to affect FPI gene 
expression, PigR. While genes on the FPI are upregulated under low iron conditions, a 
characteristic typical of Fur-regulated genes, we did not detect Fur at any promoter on the FPI. 
Based on their locations, we suggest that three proteins, PmrA, IclR, and the LysR-type 
transcription regulator FTL_1568, have a non-cannonical function, potentially as nucleoid-
associated proteins. Finally, we have constructed a model of the network of transcription factors 
involved in controlling virulence. This network model reveals a potential hierarchy of regulation 
in which FTL_0040 is implicated in the control of a large subset of transcription factors 




 Francisella tularensis is a Gram-negative, intracellular bacterium and is the etiological 
agent of tularemia. While it mostly causes disease in small mammals, humans can be infected 
via a number of routes. F. tularensis is extremely infectious and inhalation of less than ten 
aerosolized bacteria can cause disease (Tärnvik and Chu, 2007). In humans, two subspecies of 
F. tularensis cause disease; infection with F. tularensis subsp. holarctica results in relatively 
mild disease while infection with F. tularensis subsp. tularensis can cause a disease with much 
greater severity (Ellis et al., 2002). An attenuated derivative of the F. tularensis subsp. holarctica 
strain, the Live Vaccine Strain or LVS, is unable to cause disease in humans but maintains 
virulence in animal models (Eigelsbach and Downs, 1961), and we have used this strain in our 
work (which we will subsequently refer to simply as LVS). Another subspecies, F. tularensis 
subsp. novicida (referred to here as F. novicida), is also commonly used in research due to its 
inherent inability to infect immunocompetent individuals and its ability to cause disease in 
animal models. However, the combination of the highly infectious nature of F. tularensis, the 
multiple routes of infection, and the potential of some strains to cause lethal disease has lead 
the United States government to consider F. tularensis a potential bioweapon (Gallagher-Smith 
et al., 2004). Despite much recent study, there are still significant gaps in our knowledge of the 
molecular mechanisms underlying the infectious and virulent nature of F. tularensis. 
 As an intracellular pathogen, the ability to infect a host cell and subsequently survive and 
replicate is essential for F. tularensis virulence. It is clear that a particular set of genes, thought 
to encode a type VI-like secretion system, is required for intracellular survival and growth. This 
group of genes is found at the genetic locus termed the Francisella Pathogenicity Island (FPI). 
The FPI is found in all the Francisella species sequenced thus far and it appears to have been 
horizontally acquired as its GC-content is significantly lower than the rest of the genome (Bröms 
et al., 2010; Nano et al., 2004).  
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 Several transcription factors have been implicated in the control of genes present on the 
FPI. MglA and SspA are F. tularensis stringent starvation protein A (SspA) family members 
which form a heteromeric complex that interacts directly with RNA polymerase (RNAP) to 
promote the expression of virulence genes, including all those found on the FPI (Baron and 
Nano, 1998; Charity et al., 2007). Another protein, termed PigR in LVS (FevR in F. novicida), 
interacts with the MglA-SspA complex to coordinate virulence gene expression (Charity et al., 
2009). A small molecule, ppGpp, is also found to control essentially the same set of genes as 
PigR, MglA, and SspA (Charity et al., 2009). Working in concert with PigR and the MglA-SspA 
complex, ppGpp is thought to promote the interaction between the MglA-SspA complex and 
PigR (Charity et al., 2009). PmrA is an orphan response regulator in F. tularensis that has been 
demonstrated to regulate a subset of the MglA/SspA/PigR regulated genes and is proposed to 
function through a direct interaction with MglA and SspA at FPI promoters (Bell et al., 2010; 
Mohapatra et al., 2007; Dai et al., 2010).  
 While it is clear that control of the FPI and regulation by MglA, SspA, PigR, and PmrA is 
critical for virulence, many additional predicted transcription factors have been shown to be 
important for virulence. These additional transcription factors encompass most of the 
transcription factors present in the F. tularensis genome (Table 1), and in most cases it is 
unclear how they control virulence. Despite widespread identification of transcription factors 
other than MglA, SspA, PigR, and PmrA as virulence determinants, few studies have attempted 
to address how these less well-studied transcription factors affect virulence. It is not uncommon 
to see virulence regulators coordinated in a network or hierarchy to control virulence factor 
expression; there is no such network or hierarchy described in F. tularensis. Yet the information 
regarding how genes critical for virulence are coordinately regulated can provide further insight 
into the molecular mechanisms underlying pathogenesis.  
 Using chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-
Seq) (Robertson et al., 2007), we determined the direct targets of 30 transcription factors, 
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including all of those previously implicated in virulence in F. tularensis. Our findings suggest that 
in LVS, PmrA controls the expression of FPI genes indirectly and that PmrA, IclR and FTL_1568 
may function as nucleoid-associated proteins (NAPs). Furthermore, we have connected specific 
virulence regulators to the control of specific virulence genes, providing an explanation for the 
roles of several regulators in the control of virulence.  Finally, we present a model for the 





Selection of putative transcription factors for ChIP-Seq analysis 
 We sought to determine the binding sites, on a genome-wide scale, of all the 
transcription factors in F. tularensis that have been implicated in controlling virulence (Table 
3.1). To do this we performed ChIP-seq of each putative virulence regulator (Park, 2009; 
Robertson et al., 2007). In particular, we created strains of LVS that synthesized each of the 30 
transcription factors with a vesicular stomatitis virus-glycoprotein (VSV-G) epitope tag or the 
tandem affinity purification (TAP) epitope tag fused to its C-terminus, according to the scheme 
outlined in Figure 3.1. Because these strains were created by modifying the native copy of each 
gene specifying a particular transcription factor, each factor we analyzed by ChIP-Seq was 
produced at close to wild-type levels. ChIP-Seq was performed with cells grown to mid-log in 
supplemented Mueller-Hinton broth, conditions under which FPI-encoded genes that are 
important for virulence are expressed (Charity et al., 2007). 
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FTL_1743 rpoC DNA-directed RNA polymerase, β′ 
subunit 
+ - 
FTL_1050 rpoD RNA polymerase σ70 factor + - 
FTL_0851 rpoH RNA polymerase σ32 factor + (Grall et al., 2009) 
FTL_0616 rpoA2 DNA-directed RNA polymerase 
subunit α2 
- (Asare and Abu Kwaik, 2010; Asare 
et al., 2010) 
FTL_1474 greA Transcriptional elongation factor - (Asare and Abu Kwaik, 2010; Asare 
et al., 2010; Su et al., 2007) 
FTL_1185 mglA Macrophage growth locus, subunit 
A 
- (Baron and Nano, 1998; Moule et 
al., 2010) 
FTL_1606 sspA Stringent starvation protein A - (Asare and Abu Kwaik, 2010; Asare 
et al., 2010; Charity et al., 2007) 
FTL_0449 pigR Transcription factor PigR - (Brotcke and Monack, 2008; Charity 
et al., 2009; Wehrly et al., 2009) 
FTL_0428 parB Chromosome partition protein B - (Su et al., 2007) 
FTL_0552 pmrA Two-component response regulator - (Asare and Abu Kwaik, 2010; Asare 
et al., 2010; Bell et al., 2010; 
Mohapatra et al., 2007; Moule et al., 
2010) 
FTL_1364 iclR IclR family transcriptional regulator - (Asare and Abu Kwaik, 2010; 
Kraemer et al., 2009; Weiss et al., 
2007) 
FTL_1014 oxyR Oxidative stress transcriptional 
regulator 
- (Moule et al., 2010) 
FTL_1831 fur Ferric uptake regulation protein - (Deng et al., 2006) 
FTL_0662 lexA Prophage repressor protein - (Asare et al., 2010) 
FTL_1276 birA Bifunctional protein BirA - (Napier et al., 2012) 
FTL_1126 hipB Transcriptional regulator - (Asare et al., 2010) 
FTL_0370 arsR Arsenical resistance operon 
repressor 
- (Asare et al., 2010) 
FTL_1079 - Helix-turn-helix family protein - (Moule et al., 2010) 
FTL_1216 - Hypothetical protein FTL_1216 - (Asare et al., 2010) 
FTL_1222 - MarR family transcriptional 
regulator 
- (Asare et al., 2010) 
FTL_1231 - Transcriptional regulator - (Asare et al., 2010) 
FTL_1293 - Hypothetical protein FTL_1293 - (Kraemer et al., 2009) 
FTL_0040 - LysR family transcriptional regulator - (Kraemer et al., 2009) 
FTL_0062 - LysR family transcriptional regulator - (Moule et al., 2010) 
FTL_0742 - LysR family transcriptional regulator - (Moule et al., 2010) 
FTL_0844 - LysR family transcriptional regulator - (Moule et al., 2010) 
FTL_1176 - LysR family transcriptional regulator - (Moule et al., 2010) 
FTL_1193 - LysR family transcriptional regulator - (Asare and Abu Kwaik, 2010; Asare 
et al., 2010; Moule et al., 2010) 
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Table 3.1. Transcription factors analyzed by ChIP-Seq, continued 
FTL_1568 - LysR family transcriptional regulator - - 
FTL_1634 - LysR family transcriptional regulator - - 
1Based on data from F. novicida. “+”, gene is reported as a potentially essential gene; “-”, gene has not 








Figure 3.1. Schematic diagram for producing strains with epitope-tagged transcription factors. A. 
The integration vector contains a fragment of the rpoC gene (FTL_1743) followed by DNA specifying a 
VSV-G epitope tag. A single homologous recombination event produces a strain, LVS β′-V, that 
synthesizes the VSV-G tagged β′ subunit of RNAP (β′-V) from the native rpoC locus. B. The VSV-G 




chromosome rpoC chromosome 






 Because the list of virulence-associated regulators includes 7 of the 9 total LysR family 
members, we also included the 2 LysR family members not previously implicated in virulence to 
our analyses in order to study the entire LysR family. Furthermore, in order to be able to relate 
the location of any transcription regulator to a particular promoter, we determined the locations 
of RNA polymerase (RNAP) in F. tularensis. Promoter regions are defined here as regions 
enriched upon ChIP-Seq of the β′ subunit of RNAP after treatment of cells with rifampicin (rif); rif 
effectively leads to trapping of the RNAP-holoenzyme complex at promoter regions. As a 
complementary approach to determining the locations of promoters we also determined the 
locations of the two σ factors present in F. tularensis (σ70 and σ32) by ChIP-Seq (Campbell et al., 
2001; Herring et al., 2005). After merging the overlapping peaks identified by each promoter-
associated transcription factor, we found 582 putative promoter regions throughout the genome 
(see Appendix, Table S2). The majority of promoters identified are found for the most part in 
non-coding, intergenic regions (495 promoters, 85% of total).  The AT-content of promoter 
regions is enriched relative to that of the rest of the genome; while AT-content across the entire 
genome is 67.8%, promoter regions have an AT-content of 71.8%.  
We performed ChIP-Seq on 30 of the 44 putative transcription factors in LVS (Table 3.1 
and Appendix, Table S1). The chart in Figure 3.2 illustrates, for each transcription factor, the 
number of ChIP-Seq peaks that overlap with promoter regions. Because we defined promoter 
regions as those enriched for the β′ subunit of RNAP after treatment of cells with rif, or either σ 

























































































































































































































































Figure 3.2 also illustrates that the large number of MglA, SspA, and PigR peaks and 
extent of their overlap with promoter regions reflects that these proteins are found at locations 
very similar to the locations at which RNAP is found (as evidenced by both the β′ subunit and α2 
subunit) as well as locations at which the elongation factor GreA is found. This highlights that 
we identified MglA, SspA, and PigR at the majority of promoters, as described in Chapter 2. Our 
results from Chapter 2 suggest that the MglA-SspA complex may be present at all σ70-
dependent promoters, functioning to promote formation of the σ70-containing RNAP holoenzyme 
and providing a point of contact for PigR, which promotes gene expression from specific 
promoters.  
 
PmrA may indirectly control the expression of genes on the FPI and be a nucleoid-
associated protein (NAP)  
 PmrA is a key regulator of virulence gene expression in F. tularensis and, in LVS, is the 
only known response regulator. PmrA is required for virulence in mice and controls the 
expression of many genes, exerting both positive and negative effects (Mohapatra et al., 2007; 
Sammons-Jackson et al., 2008). A subset of PmrA-controlled genes are also controlled by 
MglA, SspA, and PigR in both LVS and in F. novicida, including several of those on the FPI 
(Mohapatra et al., 2007; Sammons-Jackson et al., 2008). One model specifies that PmrA exerts 
its stimulatory effects on FPI-encoded genes directly—once bound to target promoters on the 
FPI, PmrA interacts with the RNAP-associated MglA-SspA complex to activate transcription (Dai 
et al 2011). Consistent with this model, purified PmrA has been shown to bind directly to the 
pdpD promoter from the F. novicida FPI, and MglA and SspA were found to co-precipitate with 
PmrA (Bell et al., 2010). However, in LVS, where there are two copies of the FPI, PmrA controls 
the expression of FPI genes even though the FPIs do not contain the pdpD promoter region 
previously shown to bind PmrA in vitro. Whether PmrA exerts its effects on expression of FPI-
encoded genes directly in LVS was therefore not known. 
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 To determine whether PmrA might influence expression of the FPI genes directly, we 
used ChIP-Seq to determine the location of PmrA. We identified 252 regions enriched for PmrA, 
ranging from 1.5 to 536-fold enriched. Within the FPI, we found that PmrA was associated with 
3 regions, one immediately upstream of pdpE, one in the middle of pdpC, and the other 
upstream of pdpB (Appendix, Figure S1). We did not detect any association of PmrA with the 
iglA promoter (Figure 3.3) suggesting that in LVS PmrA does not exert its effects on expression 
of the igl genes by binding directly to the iglA promoter. 
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 PmrA has been shown to positively regulate expression of the pigR gene (Mohapatra et 
al., 2007; Sammons-Jackson et al., 2008). The FPI genes are also positively regulated by PigR, 
MglA and SspA, all three of which are found at the promoters of the FPI genes by ChIP-Seq 
(Figure 3.3). The results depicted in Figure 3.4 show that PmrA is detected at the pigR promoter 
and appears to have another site of significant enrichment at the 3’ end of the pigR gene. While 
the significance of PmrA enrichment downstream from the pigR promoter region is unclear, the 
presence of PmrA at the pigR promoter suggests that PmrA may be directly regulating pigR 
gene expression. Taken together, our findings suggest that in LVS, PmrA does not regulate 
expression of the igl genes on the FPIs directly. Rather, PmrA likely positively influences the 
expression of the igl genes, together with other members of the MglA/SspA/PigR regulon, by 







Figure 3.4. PmrA is found at the pigR promoter. Genomic position is indicated on the X-axis by F. 
tularensis LVS locus number; gray boxes represent genes, which are above the black line if they are 
encoded on the plus strand and below the black line if they are encoded on the minus strand. A 
representative track illustrating the density of normalized mapped sequencing reads after ChIP-Seq of 
each factor is depicted on the Y-axis. Areas of significantly enriched reads, referred to here as peaks, are 
indicated by the horizontal gray boxes below the read density plot and sites of maximum enrichment are 
indicated by the red lines. Putative promoter regions, which are areas with significant enrichment of β′ + 
rif, σ32, or σ70 association with the chromosome, are indicated by the purple horizontal boxes above the 


























The region with the highest enrichment of PmrA is found close to the FTL_0702 gene, 
whose expression is known to be negatively regulated by PmrA (Mohapatra et al., 2007; 
Sammons-Jackson et al., 2008). It therefore appears likely that PmrA functions directly as a 
repressor of the FTL_0702 gene.  
 Of the regions we identified as associated with PmrA, only 21% were found to intersect 
regions enriched for both MglA and SspA. Conversely, 74% of the regions associated with 
PmrA were not enriched for either MglA or SspA. This is in sharp contrast to our findings with 
PigR, a protein which has been demonstrated to interact directly with the MglA-SspA complex 
(Charity et al., 2009); 69% of the regions identified as enriched for PigR are also enriched for 
both MglA and SspA (see Chapter 2). The finding that the MglA-SspA complex is not found at 
many of the same locations as PmrA suggests that PmrA does not function at all locations 
through direct contact with the MglA-SspA complex.  
PmrA may not function as a canonical transcription factor at every location. Unlike MglA, 
SspA, or PigR, PmrA is found associated with many non-promoter regions; fewer than half of 
the peaks enriched for PmrA, 43%, are found at promoter regions (Figure 3.5). The lack of 
overlap between PmrA enrichment and promoters is significantly different from the 
approximately 80% or more of the regions identified by ChIP-Seq of MglA, SspA, or PigR 
associated with promoters (Figure 3.5). Because our method of defining a promoter region 
relies on our ability to detect the presence of RNAP, it is possible that the presence of PmrA at 
the 143 non promoter-associated locations is indicative of PmrA functioning as a repressor at 
these locations by occluding RNAP. However, of the PmrA-associated regions not associated 
with promoters, approximately 47% are found entirely within coding regions, a non-canonical 
location for promoter sequences. Additionally, genes associated with regions of PmrA 
enrichment (genes with translational start sites within 1 kb of the peak maximum) do not appear 
to have similar functions, as determined by cluster of orthologous group (COG) categories or by 
KEGG pathway analysis. Indeed, the abundance and diversity of PmrA ChIP-Seq peaks are 
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less suggestive of PmrA functioning solely as a canonical transcription factor and raise the 
possibility that PmrA may be more akin to a nucleoid-associated protein (NAP, Dillon and 









Figure 3.5. PmrA ChIP-Seq peaks are less frequently associated with promoters than are ChIP-Seq 
peaks of MglA, SspA, or PigR. The Y-axis indicates the percent of regions identified as enriched that 
intersect with promoters. Specific factors are labeled on the X-axis. Less than 50% of the peaks identified 
by ChIP-Seq of PmrA are promoter-associated, while approximately 80% or more of the peaks identified 




Identification of three potential NAPs in F. tularensis 
 Our ChIP-Seq analysis of PmrA suggest that PmrA may exert its effects as a 
transcription factor, at least in some instances, in a non-canonical manner, potentially through 
influencing the organization of the chromosome as a NAP. We suggest that PmrA may function 
in part as a NAP based on several observations: PmrA-associated regions are numerous, are 
found at both intergenic and intragenic locations (Figure 3.6A), and lastly, PmrA-enriched peaks 
are not more likely to be found at promoter regions than non-promoter regions; that is to say, it 
appears equally likely that highly enriched peaks would be found at non-promoter locations as 








Figure 3.6. PmrA, FTL_1568, and IclR are found at promoter and non-promoter regions. A. Percent 
of regions identified as enriched that intersect with promoters. Specific factors are labeled on the X-axis. 
Less than 50% of the ChIP-Seq peaks identified by ChIP-Seq of PmrA, FTL_1568, and IclR are promoter-
associated, while more than 80% of OxyR ChIP-Seq peaks are associated with promoters. B. Enrichment 
at peaks associated with promoters is not greater than at peaks not associated with promoters. For each 
category, box and whisker plot depicts the maximum enrichment (upper range), minimum enrichment 
(lower range), the median (center dark blue line), first (bottom of blue box), and third quartile (top of blue 
box) values, as well as the average (round yellow marker). There is no significant difference in 
enrichment between the promoter-associated and non promoter-associated peaks as assessed by Mann-














































In addition to PmrA, we found two other predicted transcription factors that have ChIP-
Seq peaks with similar characteristics: IclR and the LysR-type transcription regulator FTL_1568. 
We found that the LysR-type transcription regulator FTL_1568 is associated with 207 genomic 
locations, with regions of association ranging in enrichment from 1,223 to 1.5-fold. Of these, 89 
(43%) intersect with promoter regions (Figure 3.6A). Thus, the majority of FTL_1568 ChIP-Seq 
peaks appear to not be promoter-associated. It should be noted that it is possible that what we 
detect as a non-promoter associated ChIP-Seq peak is actually at a promoter region, but that 
under the conditions examined, the promoter is not active; in fact, a promoter region may 
specifically be inactive due to the binding of a transcription factor occluding RNAP. An inactive 
promoter is more likely to be the case for either ChIP-Seq peaks found at intergenic regions that 
have not been identified as promoters, or at regions found entirely within coding regions and 
directly upstream from an annotated translational start site. Most of the non-promoter 
associated ChIP-Seq peaks identified for FTL_1568, 64 of the 118 (54%), are found entirely 
within coding regions, less suggestive of association with a promoter and more suggestive of an 
alternate function for FTL_1568.  
 In comparison to PmrA and FTL_1568, the genomic regions of IclR association are 
similarly diverse and even more abundant. We identified 476 IclR ChIP-Seq peaks, which is 
second in terms of abundance only to promoter regions identified by ChIP-Seq of the β′ subunit 
of RNAP in the presence of rif. Regions associated with IclR ranged from 1.5 to 66-fold enriched 
for the factor. Approximately 23% (109) of these IclR-associated regions are found to intersect 
with promoter regions (Figure 3.6A). The IclR ChIP-Seq peaks that are not associated with 
promoter regions are mostly (262 of 368 or 71%) not found in intergenic regions, that is, they 
are located entirely within coding regions. Additionally, the AT-content of IclR peaks appears to 
reflect the overall AT-content of the genome rather than of promoter regions, as peak regions 
are found to consist of 66.4% AT while promoter regions are higher, at 71.8% AT. 
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As is the case with PmrA, the promoter-associated peaks of FTL_1568 or IclR are not 
significantly more enriched for each respective factor than non-promoter-associated peaks 
(Figure 3.6B). Also like PmrA, there does not appear to be any significant enrichment of COG 
categories or KEGG pathways associated with genes that are found within 1kb of the point of 
most enrichment for ChIP-Seq peaks identified for either IclR or FTL_1568. 
We have demonstrated that PmrA, FTL_1568, and IclR are all found associated with 
numerous and varied genomic locations and they do not appear to be significantly enriched in 
association with a particular class of genes or genes implicated in a particular function. Our 
findings may be consistent with PmrA, FTL_1568, and IclR not only functioning as classical 
transcription activators or repressors but also functioning more generally as factors used to 
organize the chromosome. 
 
Fur may not control expression of FPI-encoded genes directly 
 Previous studies have suggested that Fur, the ferric uptake regulator, may control the 
expression of genes on the FPI directly (Deng et al., 2006; Lenco et al., 2007). Under iron-
replete conditions, Fur binds its co-factor Fe2+, allowing it to bind the DNA. Fur typically acts as 
a repressor, binding to promoter DNA and occluding RNAP. Under conditions of iron limitation, 
Fur is no longer associated with Fe2+ and dissociates from the DNA to allow transcription. Fur is 
a site-specific DNA-binding protein and the site on the DNA to which Fur binds is referred to as 
a Fur box, as it contains a specific sequence motif. A sequence with homology to the Fur box 
identified in E. coli was found upstream of the FPI-encoded pdpB and iglC genes (Deng et al., 
2006) and when cells are grown in iron-restricted conditions, expression of the FPI genes is 
induced (Buchan et al., 2009; 2008; Deng et al., 2006; Lenco et al., 2007). This suggests that 
FPI gene expression may be controlled by Fur; however, whether Fur binds to FPI promoters 
directly has not been determined.  
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To determine if Fur binds to the promoters of the FPIs directly to repress FPI gene 
expression, we performed ChIP-Seq on cells grown in our standard iron-replete media to 
determine the location of Fur. We identified 21 Fur ChIP-Seq peaks; Fur ChIP-Seq peaks with 
associated genes (genes with translational start sites within either 100 bp upstream or 1 kb 
downstream from the maximum point of Fur enrichment) are listed in Table 3.2. As indicated in 
Table 3.2, expression of many of the genes associated with Fur ChIP-Seq peaks has been 
shown to change in response to low iron conditions (Deng et al., 2006). We did not detect any 
enrichment of Fur in the FPI, suggesting that Fur does not control expression of the FPI genes 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The two most highly enriched Fur ChIP-Seq peaks are found at the fsl (or fig) operon, 
between the end of the fur gene and upstream of fslA, and between fslD and fslE (Figure 3.7). 
The fsl operon encodes a siderophore biosynthesis and uptake system used for iron uptake 
(Deng et al., 2006; Sullivan et al., 2006). Other Fur ChIP-Seq peaks are associated with genes 
coding for proteins involved in amino acid biosynthesis or other transport proteins, including an 
alternate iron uptake protein encoded by feoB (Thomas-Charles et al., 2013). Of the 21 Fur 
ChIP-Seq peaks, only two are found to intersect with promoter regions. This is consistent with 
the role of Fur as a repressor that binds to the promoters of Fur-regulated genes and occludes 






Figure 3.7. Regions of Fur enrichment are found at the fsl operon. Genomic position is indicated on 
the X-axis by F. tularensis LVS locus number; gray boxes represent genes, which are above the black 
line if they are encoded on the plus strand and below the black line if they are encoded on the minus 
strand. A representative track illustrating the density of normalized mapped sequencing reads after ChIP-
Seq of each factor is depicted on the Y-axis, β′+ rif (purple), σ70 (aqua), and Fur (green). Areas of 
significantly enriched reads, peaks, are indicated by the horizontal gray boxes below the read density plot 
and sites of maximum enrichment are indicated by the red lines. Putative promoter regions, which are 
areas with significant enrichment of β′ + rif, σ32, or σ70 association with the chromosome, are indicated by 










































































The specific DNA sequence that Fur binds, the Fur box, has been described in E. coli 
and Bacillus subtilis as a 19-21 bp motif consisting of several repeats of a GATAAT hexamer, 
with the hexamer existing in several possible orientations (Baichoo and Helmann, 2002). Using 
MEME, we examined all of the sequences associated with the F. tularensis Fur ChIP-Seq peaks 
(Bailey and Elkan, 1994). We identified a 14 bp motif that contains elements of the Fur box 
GATAAT hexamer; we refer to the identified motif as the Ft-Fur box (Figure 3.8A and B). 
Although we have only found Fur associated with 21 regions, the Ft-Fur box sequence can be 
found 1,003 times in the LVS genome (motif sequences found with p < 0.0001; Grant et al., 
2011). It seems reasonable that the likelihood of Fur associating with a particular Fur box is 
modulated by a number of factors, including the amount of Fur in the cell, the relative affinity Fur 
has for a particular sequence and the occupancy of other protein factors nearby. Consistent with 
the idea that Fur binding may be in part influenced by the affinity of Fur for a particular 
sequence, if we only search for a motif in 10 regions most enriched for Fur, a different 
consensus motif is identified (Figure 3.8C and D), which may be closer to the ideal Fur binding 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A sequence similar to the Fur box described in E. coli and B. subtilis has been identified 
within 100 bp of the annotated translational start sites for the iglC and pdpB genes. Despite the 
widespread presence of the Ft-Fur box, it was not detected within 1 kb of the annotated 
translational start site of the pdpB gene. The closest Ft-Fur box upstream of iglC is 566 bp from 
the annotated translational start site. However, the iglABCD genes are thought to consist of an 
operon, under the control of the iglA promoter (Appendix, Figure S1; Buchan et al., 2008). We 
do not find any evidence of an alternate promoter for the iglC gene, and there does not appear 
to be a Ft-Fur box within 1 kb of the iglA transcriptional start site. Thus, it seems unlikely that 
Fur would directly associate with FPI promoters to regulate gene expression.  
 
Identification of the regulatory targets of OxyR and FTL_0040  
Of the transcription factors we studied, many are, like Fur, found mostly at a few 
promoter or intergenic regions, suggesting they may regulate genes in a manner similar to 
canonical transcription activators or repressors. For each of the putative site-specific DNA 
binding proteins we examined, we have identified all the associated genes (genes which have 
translational start sites within either 100 bp upstream of or within 1kb downstream of the 
maximum point of enrichment of the factor) and proposed a putative regulon (see Appendix, 
Tables S3-S16). By identifying the direct targets of a virulence-associated transcription factor, 
we may be able to identify the gene(s) responsible for the transcription factor’s contribution to 
virulence and reveal the regulatory hierarchy in the cell. We have specifically documented the 
virulence-associated genes found within the regulons of two factors, OxyR and the LysR-type 
transcription regulator FTL_0040.  
 In E. coli, the LysR-type transcription regulator OxyR typically functions as an activator 
and is responsible for initiating a cellular program in response to oxidative stress. In F. 
tularensis, the OxyR homolog has been implicated in virulence (Moule et al., 2010; Zheng et al., 
2001). Specifically, a mutant of F. novicida containing a transposon insertion in oxyR was 
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attenuated for virulence in a Drosophlia model of infection (Moule et al., 2010). We found OxyR 
to be enriched at 27 genomic regions and identified 54 associated genes (Table 3.3). One of the 
genes associated with OxyR enrichment is oxyR itself, suggesting that in F. tularensis, as in E. 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































About half of the OxyR ChIP-Seq peaks, 13, are associated with a total of 19 genes 
previously implicated in virulence (Table 3.3). Only one of the virulence genes associated with 
OxyR ChIP-Seq peaks, aroE, was found in the same screen that originally identified OxyR as 
important for virulence (Moule et al., 2010). This raises the possibility that the attenuation 
phenotype of the oxyR mutant might be explained entirely through the effect of OxyR on aroE 
expression. It is also possible that the attenuated phenotype of the oxyR mutant might be 
explained by the effects of OxyR on any of the other 18 virulence genes it might control. Indeed, 
while OxyR is found associated with a promoter upstream of the aroE gene, there is another 
separate promoter region closer to the translational start site of aroE that OxyR is not 
associated with, which suggests that the OxyR-associated promoter may not be the promoter 
that controls aroE expression. The observed virulence defect of the OxyR mutant, then, may be 
related to the misregulation of one or more of the other 18 virulence-associated genes within the 
putative OxyR regulon. Together, this work suggests that OxyR coordinately regulates a number 
of virulence factors, including other transcription regulators that control virulence. 
 In F. novicida, a mutant containing a transposon insertion in the gene encoding the 
homolog of the LysR-type transcription regulator FTL_0040 was specifically attenuated for 
dissemination to the spleen in a mouse inhalation model of infection (Kraemer et al., 2009). In 
LVS, we identified 18 regions of FTL_0040 enrichment, 11 of which are found near translational 
start sites of genes (Table 3.4). The gene FTL_0040 is associated with the most highly enriched 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Of the 11 FTL_0040 ChIP-seq peaks, 7 are associated with genes implicated previously 
as virulence factors through a variety of studies (Table 3.4). Four genes associated with 
FTL_0040 enrichment peaks, sbcB, FTL_1902, tyrA, and gph, were also identified in the screen 
that originally implicated FTL_0040 in virulence (Kraemer et al., 2009). FTL_1902 encodes a 
hypothetical protein predicted to localize to the membrane, and a FTL_1902 mutant was, like a 
FTL_0040 mutant, found to be specifically attenuated for dissemination to the mouse spleen 
(Kraemer et al., 2009). This suggests that the specific virulence defect observed with the 
FTL_0040 mutant might be completely explained by the loss of FTL_1902 expression in the 
FTL_0040 mutant. By determining the targets of FTL_0400 by ChIP-Seq we may have identified 
a pathway directly involved in signaling the production of factors required for infection of a 
specific niche.  
 
A model of the virulence regulatory network in F. tularensis 
The ChIP-Seq analysis of the putative OxyR and FTL_0040 regulons reveals that both 
transcription factors are found at the promoters of genes encoding other transcription factors. 
Our data also indicate that one function of PmrA may be to control gene expression indirectly 
through its direct effect on the expression of pigR. Given these relationships between 
transcription factors, we asked if we could identify a network or hierarchy of transcription factor 
regulation.  
 We examined the regulon of each transcription factor as determined by ChIP-Seq and 
asked if any regulon members encoded a transcription factor. Because PigR is found at 
essentially all promoters, we excluded its potential effect on any transcription factor apart from 
the documented effect of PigR on its own promoter (Charity et al., 2009). We also excluded 
from our analyses the putative NAP IclR, as previously reported microarray results suggest that 
IclR does not influence the expression of any genes encoding a transcription factor (Mortensen 
et al., 2010). We have suggested that PmrA controls gene expression, at least in part, by 
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promoting the expression of pigR, and so we only included the documented effect of PmrA on 
pigR expression (Mohapatra et al., 2007; Sammons-Jackson et al., 2008).   
 Figure 3.9 illustrates a model of the virulence regulatory network in F. tularensis 
revealing the connections between different virulence regulators. OxyR is found at the 
promoters of the genes encoding PigR and ArsR, both of which have been implicated in 
virulence, as well as the FTL_1967 locus, which has not been implicated in virulence. FTL_0040 
appears to regulate an entire section of the network. FTL_0040 is found at the promoter of 
another transcription factor demonstrated to be important for virulence, FTL_0742, as well as at 
the promoter of FTL_1568, which has not been associated with virulence. However, FTL_1568 
is found at the promoter regions of five other transcription factors, all of which have been 
previously implicated in virulence. The net result of these interactions suggests that FTL_0040 
may be at the top of a regulatory hierarchy, regulating the expression of six other transcription 
factors important for F. tularensis pathogenesis. 
 The network depicted in Figure 3.9 also reveals that multiple transcription factors 
implicated in virulence may regulate their own expression. For one factor, we only detected 
enrichment of the factor at its own putative promoter (ArsR, see Appendix, Table S7). In this 
instance it is unclear whether the factor controls the expression of itself in addition to virulence 
genes present in the same operon, or whether the factor binds other regions involved in 
virulence that are not detected in our analyses. Generating a model of the regulation of 
transcription factors, such as in Figure 3.9, provides insight into the complexity of gene 
regulation in F. tularensis and provides us with the opportunity to generate new hypotheses 
regarding virulence factor regulation. 










Figure 3.9. The network of virulence regulators in F. tularensis LVS. Circles indicate transcription 
factors; those in red have previously been implicated in virulence while those in blue have not. Arrows 
indicate the presence of a transcription factor at the putative promoter of the gene encoding another 





We have performed ChIP-Seq on 30 transcription factors in F. tularensis LVS, including 
all those implicated in the control of virulence gene expression. By determining the location of 
each transcription factor, we have been able to predict potential regulons under the direct 
control of each factor. For the predicted OxyR and FTL_0040 regulons, we have determined 
which regulon members have previously been implicated in virulence, allowing us to offer 
possible explanations for how each of these regulatory factors directly contributes to virulence. 
We have presented evidence that the positive effect of PmrA on the expression of genes 
located on the FPI may be indirect, through PmrA promoting pigR expression. Additionally, 
PmrA may be functioning along with FTL_1568 and IclR as a NAP. We have described the 
putative regulon of the ferric uptake regulation protein, Fur, and demonstrated that it may not 
directly control the expression of FPI-encoded genes. Finally, we have been able to generate a 
model of the regulatory network that controls virulence in F. tularensis, suggesting a regulatory 
hierarchy. 
We identified 3 transcription factors which may act in part as NAPs, specifically PmrA, 
FTL_1568, and IclR. The ChIP-Seq peaks identified for the putative NAPs vary widely with 
respect to fold enrichment, suggesting that some sites may be high affinity sites while others 
may be weaker in affinity for the particular factor. However, the relationship between fold 
enrichment and affinity of a particular transcription factor for a given site is not well 
characterized. There are multiple factors that determine the extent to which a transcription factor 
associates with a particular region. Degree of occupancy of a particular site might be influenced 
by the affinity the factor has for a particular site, by competition with other factors for the 
available site, and by nucleoid structure; relative enrichment values in our identification of ChIP-
Seq peaks do not necessarily correlate to relative binding affinity.  
Many of the ChIP-Seq peaks for PmrA, FTL_1568, and IclR are poorly-enriched sites, 
that is, are enriched less than 2-fold (24%, 30%, and 21% of ChIP-Seq peaks for PmrA, 
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FTL_1568, and IclR, respectively). Sites with widespread weak enrichment for a particular 
transcription factor have been reported in eukaryotes (Farnham, 2009; Galagan et al., 2013b; 
MacQuarrie et al., 2011) and prokaryotes (Chumsakul et al., 2013; Galagan et al., 2013a; 
2013b). In Mycobacterium tuberculosis, at least a subset of weak association sites appear to be 
functional, in that they affect the regulation of the surrounding gene(s) (Galagan et al., 2013a). It 
is possible that these poorly enriched sites are lower in affinity for the particular transcription 
factor and would be more highly enriched in the context of greater transcription factor 
abundance, as has been demonstrated in M. tuberculosis (Galagan et al., 2013a). Identification 
of weakly enriched sites could also result from proteins that are merely found in close proximity 
to specific regions of DNA, such as regions where DNA may be tightly compacted in a specific 
structure.  
Enrichment of PmrA, IclR, and FTL_1568 is, at their respective most enriched ChIP-Seq 
peak, relatively high in comparison to the other factors this study has examined. It might be 
argued then that all transcription factors occupy a range of high and low enrichment sites and 
the only reason we see many poorly enriched sites for these three factors is because they are 
more easily detected by ChIP-Seq than others we have examined. However, we have not 
necessarily found that having ChIP-Seq peaks with very high enrichment always correlates to 
having many peaks with low enrichment. One LysR-type transcription regulator in particular, 
FTL_1222, is found to be essentially as enriched as FTL_1568 at its highest ChIP-Seq peak 
(1,126-fold versus 1,223-fold enriched, respectively), and more enriched than the highest PmrA 
ChIP-Seq peak (1,126-fold versus 536-fold). However, rather than being found at hundreds of 
locations across the genome, FTL_1222 is only associated with three. This suggests that the 
correlation between high enrichment and ChIP-Seq peak abundance is not absolute and 
suggests that the large numbers of peaks identified are not artifacts of the ChIP-Seq protocol.  
Potential artifacts of ChIP-Seq experiments are a concern, as a recent paper 
demonstrating that certain highly-transcribed regions of the eukaryotic Saccharomyces 
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cerevisiae genome are easily identified by ChIP-Seq, even when using a heterologous control 
protein that is not known to bind DNA (Teytelman et al., 2013). However, our data seem to be 
close to ideal in terms of avoiding artifacts resulting from highly-transcribed regions. In this 
study, we compare DNA specifically immunoprecipitated from cell lysates containing the 
epitope-tagged transcription factor of interest (IP DNA) to DNA non-specifically 
immunoprecipitated from cell lysates lacking epitope-tagged protein (mock IP DNA). Both DNA 
samples undergo some selection using the same antibody-decorated beads. Similar to the 
results of Teytelman et al., we find that even in the mock IP DNA, immunoprecipitation results in 
enrichment of particular genomic regions (data not shown, Brencic et al., 2009), which we can 
effectively subtract from further analyses. But in the analysis of S. cerevisiae, certain regions 
were still found to be consistently enriched when a protein was immunoprecipitated, even a 
heterologous, non-DNA-binding protein such as GFP. Therefore, the authors suggest 
comparing peaks found using a similar heterologous control to peaks specifically identified using 
the transcription factor of interest, or to at least compare many datasets. The work presented 
here consists of 30 ChIP-Seq experiments of different factors performed in triplicate using the 
same protocol, all of which are compared to the mock IP experiment. Thus, we have generated 
a large dataset in which to detect potential artifacts from highly-expressed regions. While it is 
notable that one factor in particular, FTL_1231, is mostly weakly enriched at the highly-
transcribed tRNA genes, we do not see a specific pattern of enrichment common to ChIP-Seq of 
all transcription factors. This suggests that ChIP-Seq of highly transcribed regions is not a 
significant problem in our dataset. 
It is entirely possible, however, that detecting artifactual ChIP-Seq enrichment at highly-
expressed loci is dependent on a certain level of protein expression. In our experiments, 
transcription factors are expressed from their native promoter on the chromosome. The level of 
native expression is likely to be different for each factor. In fact, ChIP-Seq of several 
transcription factors, FTL_1216, FTL_0844, and FTL_1634, did not identify any peaks. This may 
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reflect a lack of protein expression under the conditions used; consistent with this, when 
generating strains that would produce the epitope-tagged proteins encoded by FTL_1216, 
FTL_0844 and FTL_1634, we could not detect epitope-tagged protein by Western blot.  
A technical limitation of our approach to ChIP-Seq lies in our use of epitope-tagged 
factors to determine the location of DNA-associated proteins. It is possible that the addition of 
the epitope tag interferes with the function of one or more factors, potentially reducing their 
ability to bind DNA. However, we were able to identify ChIP-Seq peaks for 90% of the factors 
we performed ChIP-Seq upon, implying that the addition of the epitope tag did not completely 
abolish the association of the factor with DNA for most factors.  
We compared the location of ChIP-Seq peaks for PmrA and IclR to reported 
transcriptomic data in order to correlate transcription factor binding with potential function 
(Mortensen et al., 2010; Sammons-Jackson et al., 2008). In the case of both PmrA and IclR, we 
found poor correlation between reported regulated genes and genes associated with a ChIP-
Seq peak. Specifically, of the 17 genes whose expression is altered in the absence of IclR 
(Mortensen et al., 2010), only 7 are found with translational start sites within 1kb of an IclR 
ChIP-Seq peak maximum. PmrA is reported to control the expression of 155 genes in LVS 
(Sammons-Jackson et al., 2008), but only 35 were found to have a translational start site within 
1 kb of a PmrA ChIP-Seq peak maximum. These findings are consistent with the idea that IclR 
and PmrA do not always function as canonical transcription factors and may exert some of their 
effects on gene expression indirectly.  
A study of PmrA in F. novicida has also reported transcriptomic data and there is poor 
correlation between the genes reported to be regulated by PmrA in LVS and F. novicida; of the 
65 PmrA-regulated genes reported in F. novicida (Mohapatra et al., 2007), only 5 overlap with 
the 155 PmrA-regulated genes in LVS (Sammons-Jackson et al., 2008). Genes positively 
regulated by PmrA in both analyses include three genes located on the FPI and pigR; the one 
gene shown to be negatively regulated by PmrA in both studies is the gene encoding the 
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hypothetical protein FTL_0702, which is a gene associated with the most highly enriched PmrA 
ChIP-Seq peak. The apparently poor overlap in regulons between the two strains raises the 
possibility that there may be some strain-specific differences in the role of PmrA on gene 
expression.  
It should be noted that, in our comparative analysis of trancriptiomic data and ChIP-Seq 
data, there are a number of caveats. The lack of correlation between identified regulated genes 
in previous studies and identified ChIP-Seq peaks from this work is also consistent with 
differences in a number of experiment-specific possibilities. These include growth media specific 
or growth phase specific effects, or differences between detection limits for microarray versus 
ChIP-Seq experiments.   
However, it is also a possibility that many of the individual ChIP-Seq peaks we have 
identified for PmrA, FTL_1568, and IclR, all of which exhibit widespread genomic association in 
both promoter and non-promoter locations, do not result in detectable regulatory consequences 
on nearby genes. Rather than to regulate gene expression, these sites may be important to 
regulate chromosome structure and reflect a NAP function for PmrA, FTL_1568, and IclR. In 
fact, LysR-type transcription regulators such as FTL_1568 are thought to function, at least in 
part, to activate or repress transcription by binding and bending DNA, which would be consistent 
with a role both in transcription regulation and chromosome organization. The binding and 
bending of DNA by transcription factors may have additional consequences; it has been 
suggested that transcription factor binding may influence the accessibility of DNA to both 
mutagenic agents and repair enzymes (Warnecke et al., 2012). Thus, transcription factor 
binding within coding regions, by proteins such as PmrA, FTL_1568, and IclR may have 
biological consequences for the evolution of a gene (Warnecke et al., 2012). 
Work performed in F. novicida has resulted in a model for how PmrA controls the 
expression of virulence genes present on the FPI (Bell et al., 2010). In this model, PmrA is 
proposed to bind directly to promoter regions on the FPI and function as a transcription activator 
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by interacting with the RNAP-associated MglA-SspA complex (Bell et al., 2010). Using ChIP-
Seq in LVS, we failed to detect PmrA at either the iglA or pdpA promoters, suggesting that 
PmrA does not influence the expression of FPI genes directly in this organism. While it is 
possible that our inability to detect PmrA at the iglA and pdpA promoters simply reflects an issue 
with the sensitivity of our detection method, we did reproducibly detect PmrA at many other 
regions with enrichment values between 1.5 and 536-fold. Nevertheless, we did detect PmrA at 
the pigR promoter using ChIP-Seq and PmrA has been shown to positively regulate pigR 
expression (Mohapatra et al., 2007; Sammons-Jackson et al., 2008). Furthermore, our ChIP-
Seq studies identified MglA, SspA, and PigR associated with FPI promoters, which suggests 
that the role of MglA, SspA, and PigR on FPI gene expression is direct. Our findings with ChIP-
Seq are more consistent with an alternative model in which PmrA influences the expression of 
genes on the FPI indirectly through an effect on expression of pigR (Meibom et al., 2009a; 
Figure 3.10). Through the regulation of the PigR transcription factor, PmrA may indirectly control 
the entire PigR regulon. 
 
139
	    














































































































































































































































































 The host intracellular environment is thought to have a limited amount of easily 
accessible iron (Caza and Kronstad, 2013; Schaible and Kaufmann, 2004), and iron limitation 
promotes expression of the FPI-encoded virulence genes in F. tularensis (Buchan et al., 2008; 
2009; Deng et al., 2006; Lenco et al., 2007). However, the mechanism behind this regulation is 
unclear. Because Fur is considered the major iron-responsive transcription factor, it is an 
attractive candidate for regulation of genes affected by iron abundance and putative Fur boxes 
were identified at FPI promoters (Deng et al., 2006). However, several studies have suggested 
that Fur does not directly regulate FPI gene expression (Buchan et al., 2008; 2009). Our results 
are consistent with these data, as we did not detect Fur association with FPI promoters. 
Additionally, our studies identified a Fur box sequence specific to F. tularensis, the Ft-Fur box, 
which is not identified near FPI promoter regions. Thus, it seems likely that another mechanism 
is responsible for promoting FPI gene expression in low iron conditions. In E. coli, SpoT appears 
to promote ppGpp formation under conditions of iron limitation (Vinella et al., 2005). In LVS, 
SpoT is required for FPI gene expression as well as intramacrophage growth and virulence 
(Charity et al., 2009). It is therefore possible that SpoT is the factor that, in response to low iron, 
promotes FPI gene expression in F. tularensis by promoting ppGpp formation.    
 While this point is implicit, it should be reiterated that transcription factors are considered 
virulence factors because they control the production of virulence factors. The LysR-type 
transcription regulators OxyR and FTL_0040 have been identified as virulence factors (Kraemer 
et al., 2009; Moule et al., 2010) and this work elucidates the virulence factors they are likely to 
regulate. While the identification for OxyR and FTl_0040 as virulence factors only reflects that 
they are necessary to regulate at least one virulence factor, both have putative regulons that 
contain multiple factors linked to virulence. This work suggests that both OxyR and FTL_0040 




 The OxyR regulon, based on work in other organisms, is generally thought to include 
genes required for the detoxification of reactive oxygen or nitrogen species (reviewed in Imlay, 
2013). The genes implicated by ChIP-Seq as members of the LVS OxyR regulon appears to be 
similar to other OxyR homolog regulons (Wei et al., 2012; Zheng et al., 2001). Specifically, 
OxyR is found at the promoter of katG, which encodes catalase, and at the promoter of a gene 
encoding an AhpC family protein. Both of these proteins are commonly found under the control 
of OxyR, as they are used to detoxify hydrogen peroxide. The most enriched OxyR ChIP-Seq 
peak is at the promoter region of a gene annotated as encoding a hypothetical protein, 
FTL_1717. Upon further examination, it appears that this gene encodes the F. tularensis LVS 
homolog of the E. coli YaaA protein and so has been referred to as such in Table 3.3. In E. coli, 
yaaA is part of the OxyR regulon and its protein product has been shown to be important for 
lowering intracellular iron levels, although its mechanism of action is still unknown (Liu et al., 
2011; Zheng et al., 2001). There are a few differences between the OxyR regulon in F. 
tularensis and other organisms; in E. coli, OxyR binds the fur promoter to directly regulate Fur 
expression (Zheng et al., 1999), but we do not detect enrichment of OxyR at the Fur promoter. 
Some differences are possibly due to the lack of F. tularensis homologs of OxyR regulon 
members found in other bacteria, such as the lack of a F. tularensis homolog for dps, which, in 
other bacteria, encodes a gene important to scavenge iron (reviewed in Imlay, 2013).   
 The studies of OxyR and FTL_0040 also highlight another important point regarding the 
information to be gleaned from this body of work. Each transcription factor linked to virulence 
was identified in a specific screen using a specific model for F. tularensis pathogenesis. As F. 
tularensis successfully proceeds through an infection, it must adapt and respond to a number of 
different environments in a variety of different cell types, organs, and even hosts. Many of these 
screens identify the same virulence factors, which are interesting because they seem to be 
universal to infection of all cells, organs, and hosts. Yet tropisms in infection, that is, preferences 
in infection sites or specific niches, can reveal important biological information about both the 
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pathogen and the host. At least some of the transcription factors in this study may be 
dispensable for virulence in a number of models, but have been found to be critical in at least 
one. This suggests that there are biologically relevant pathways required in, and possibly unique 
to, particular models of infection. By identifying the direct targets of transcription factors critical 
for pathogenesis within the context of different infections, we can start to identify these cell-, 
organ-, or host-specific pathways through which F. tularensis causes disease and learn more 
about specific infection tropisms.  
 The genes located on the FPI are essential for intracellular survival and growth and are 
required for virulence (Bröms et al., 2010). We have replicated the result that FPI gene 
expression is reduced in cells lacking PigR (Chapter 2, Table 2.2, Brotcke and Monack, 2008; 
Charity et al., 2009) and have found PigR at the FPI promoters (Figure 3.3), indicating that PigR 
directly promotes FPI gene expression. However, pigR expression may be subject to regulation 
by a number of factors. It is known that pigR is regulated by its own protein product and by MglA 
and SspA (Brotcke et al., 2008; Charity et al., 2009). It also appears that PmrA is a direct 
regulator of pigR expression (Figure 3.3; Mohapatra et al., 2007; Sammons-Jackson et al., 
2008). The presence of OxyR, FTL_1568, and IclR are all detected upstream of the pigR 
promoter along with MglA, SspA, PigR, and PmrA. Additionally, expression of pigR appears to 
be subject to control by the small molecule ppGpp, which seems to promote, either directly or 
indirectly, the interaction between PigR and the MglA-SspA complex. Thus, regulation of pigR 
expression appears to be a critical step in regulating FPI gene expression.  
 Ultimately our data have led to a model for the network of transcription factor regulation 
in F. tularensis (Figure 3.9). The model of transcription regulation we have proposed highlights 
the interconnected relationships that exist between transcription regulators. This illustrates an 
important advantage of using ChIP-Seq to identify targets of regulation, in comparison to a 
transcriptomic approach. Generally, transcriptomic approaches compare cells lacking a protein 
to cells containing the protein of interest. This is a powerful approach, but if removal of one 
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transcription factor impacts the production of another transcription factor, it can be difficult to 
distinguish direct effects from indirect effects. An example of the ambiguity inherent to 
transcriptomic data is provided by PmrA. While microarray data are consistent both with PmrA 
directly regulating FPI gene expression and with PmrA indirectly regulating FPI gene expression 
through PigR, the PmrA ChIP-Seq data suggests that PmrA indirectly affects FPI gene 
expression through PigR.  
 It should be noted that we did not find much evidence of functional redundancy, i.e. 
significant overlap of operons, within the regulons of LysR family members or between other 
transcription factors. There are genes with promoters that intersect with the ChIP-Seq peaks of 
multiple family members, such as the FTL_1568 promoter, at which FTL_0040 is found with 
FTL_1568 itself. This could be indicative of co-regulation where these two members of the LysR 
family function together to control the expression of a particular gene. It is also possible that 
they recognize identical or overlapping DNA sequences and compete with one another for the 
available site(s). In this latter case, our observations would reflect the existence of a subset of 
cells with one factor associated with the promoter region, and another subset of cells with the 
other factor associated.  
 We found a number of transcription factors at their own promoter; of 20 factors (those for 
which we detected ChIP-Seq peaks, excluding RNAP subunits, the elongation factor GreA, 
MglA, and SspA) 9, or 45%, are detected near their putative promoter region. Autoregulation is 
a common feature of LysR-type transcription regulators, and we detected evidence of this for 
three of the seven LysR family members. We additionally found evidence of autoregulation for 
three proteins that are characterized in other species as repressors: LexA, HipB, and ArsR. 
PigR is found at its own promoter, and has previously been shown to regulate its own 
expression (Brotcke and Monack, 2008; Charity et al., 2009). The remaining proteins that are 
potentially autoregulatory are the two hypothetical transcription factors FTL_1079 and 
FTL_1222, both of which contain predicted helix-turn-helix motifs.  
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 By determining the location of many transcription factors across the genome, we have 
gained insight into gene regulation in F. tularensis in a number of ways. This work has 
suggested alternate models for gene regulation of specific virulence factors critical for F. 
tularensis pathogenesis. Additionally, these data have led us to suggest that several proteins 
may play a role in chromosomal organization, which may open new and interesting lines of 
inquiry. Finally, while attempting to parse how transcription factors influence gene expression, 
we have gained new insights into how these factors are connected and the regulation to which 




Materials and Methods 
Plasmids, strains, and growth conditions 
 F. tularensis subsp. holarctica LVS was grown at 37°C in either Mueller Hinton (MH) 
broth (Difco) supplemented with glucose (0.1%), ferric pyrophosphate (0.025%), and Isovitalex 
(2%), or on cysteine heart agar (Difco) medium supplemented with 1% hemoglobin solution 
(VWR); when appropriate, kanamycin was used for selection at 5 µg/ml. E. coli strain XL1-blue 
(Stratagene) was used for plasmid construction and, when appropriate, kanamycin was used to 
select for resistance at 50 µg/ml.  
 
Integration vectors, strain construction, Southern blotting and immunoblots 
Integration constructs and strains were generated and confirmed as in Chapter 2. For 
genes whose putative operons may be interrupted by plasmid integration, a plasmid that 
promotes transcription downstream from the integrated plasmid was generated, as described in 
Chapter 2. This strategy was necessary to add the DNA encoding the epitope tag to both the 
sspA and pmrA genes.  
 
Chromatin Immunoprecipitation (ChIP), Illumina Library Preparation, ChIP-Seq data analysis 
 ChIP was performed in biological triplicate (excepting β′ + rifampicin, OxyR, and LVS 
∆pigR pF-PigR-V, which were performed in duplicate and σ70, which was performed in 
quadruplicate) as described in Chapter 2. Library preparation for Illumina sequencing and 
subsequent data analysis were performed as described in Chapter 2.  
 
MEME 
 To identify a common motif in Fur ChIP-Seq peaks, the 300 bp region surrounding the 
site of maximum Fur enrichment for each Fur ChIP-Seq peak was identified. The first Fur motif 
(Figure 3.8A and B) was identified by searching all of the Fur ChIP-Seq peaks for a common 
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motif using MEME; the second Fur motif (Figure 3.8C and D) was identified by searching only 
the ten most enriched Fur ChIP-Seq peaks using MEME (Bailey and Elkan, 1994). FIMO (Grant 
et al., 2011) was subsequently used to identify the occurrences of each motif in the F. tularensis 
LVS genome.  
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 Francisella tularensis is the causative agent of the disease tularemia. As an intracellular 
pathogen, F. tularensis must be able to survive inside the host cell. One of the first genetic loci 
found to be critical for intracellular survival was named macrophage growth locus A, or mglA 
(Baron and Nano, 1998). A stringent starvation protein A (SspA) family member, MglA has since 
been found to be a transcription regulator essential to activate the transcription of genes critical 
for virulence encoded on the Francisella pathogenicity island (FPI) (Lauriano et al., 2004). 
Recent work has demonstrated that MglA functions as a heteromer with its homolog, SspA, in 
concert with another protein, PigR, to regulate gene expression (Brotcke and Monack, 2008; 
Charity et al., 2009).  
Our laboratory previously proposed a model to explain how MglA, SspA, and PigR 
regulate a common set of genes. According to this model, PigR, a putative DNA-binding protein, 
binds to a specific DNA sequence at target promoters. At these locations, PigR would interact 
directly with the RNA polymerase (RNAP)-associated MglA-SspA complex to stabilize RNAP at 
the promoter and increase transcription of specific target genes (Charity et al., 2009). 
Between our work and other studies, we are continuing to gain insight into the 
mechanisms by which MglA, SspA, and PigR function to regulate virulence gene expression. 
However, while a large number of other F. tularensis transcription factors have been implicated 
in virulence, very little is known about their role in regulating virulence factors. Transcription 
networks and hierarchies have been uncovered that govern the production of virulence factors 
in many other bacteria, but none have been described in F. tularensis. 
 Elucidating how virulence factors are coordinately regulated, by all transcription factors, 
will allow further insight into the mechanisms by which F. tularensis causes pathogenesis. 
Additionally, while we have proposed a model for the manner in which MglA, SspA, and PigR 
function to regulate gene expression, several features of this model had yet to be experimentally 
tested. These include that PigR is a site-specific DNA binding protein that is only found at target 
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promoters, and that MglA, SspA, and RNAP should be found together at target promoters with 
PigR.  
 In order to both answer specific questions regarding the mechanisms by which MglA, 
SspA, and PigR regulate virulence gene expression, as well to determine the direct targets of 
the other virulence-associated transcription regulators in F. tularensis, I performed chromatin 
immunoprecipitation followed by high-thoughput sequencing (ChIP-Seq) on a total of 31 F. 
tularensis transcription factors, which includes all of the transcription factors previously 
implicated in virulence and 70% of the total number of transcription factors thought to be present 
in F. tularensis LVS. This allowed me to identify all of the genomic regions associated with each 
transcription factor examined. As a result, we have revised our model of virulence gene 
regulation by MglA, SspA, and PigR, and have identified the putative direct targets for all of the 
transcription factors analyzed. In addition, these studies have led to several other hypotheses 
regarding virulence-associated transcription factors, including that several, specifically PmrA, 
IclR, and the LysR-type transcription regulator FTL_1568, may function as nucleoid-associated 
proteins (NAPs). I have made a connection between several virulence-associated transcription 
factors and specific genes previously proposed to be important for virulence, and finally, have 
presented a model describing the network of transcription factors controlling virulence in F. 
tularensis.  
 As described in Chapter 2, I detected MglA, SspA, and PigR at virtually every promoter 
region across the genome. This suggests that if PigR is a site-specific DNA-binding protein, the 
PigR-specific site would have to be present at all promoter regions. In this case, we 
hypothesized that PigR may bind the promoter-specific site regardless of the presence of the 
MglA-SspA complex. However, I did not detect PigR at promoter regions in the absence of 
MglA. This indicates that PigR requires MglA (and thus presumably, the MglA-SspA complex) to 
associate with promoter regions.  
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 Since MglA, SspA, and PigR are found together at virtually all promoter regions and 
appear to control the same set of genes (Brotcke and Monack, 2008; Charity et al., 2009), it 
would be logical to suggest that these three proteins function together and control exactly the 
same genes. However, I observed a difference between cells lacking MglA in comparison with 
cells lacking PigR; as previously reported, cells lacking MglA had a slow growth phenotype 
(Charity et al., 2007; Honn et al., 2012), but cells lacking PigR grew similarly to wild-type cells. I 
therefore reasoned that there might be some differences between the genes that PigR and 
MglA regulate, and that MglA may be important in regulating genes critical to maintaining 
normal growth.   
 To determine if there are differences between the regulons of MglA and PigR, I 
assessed the transcript levels of a subset of F. tularensis genes, including genes reported to be 
positively or negatively regulated by MglA as well as those not known to be regulated by MglA, 
SspA, or PigR. I found that despite the concordance in localization as determined by ChIP-Seq, 
there are critical differences between the functions of MglA, SspA, and PigR. In association with 
MglA, PigR functions as a positive regulator. However, MglA also appears to function to repress 
gene expression independently of PigR.  
 In order to determine if there are any sequences specific to promoters that are 
responsive to PigR, I searched for a conserved motif upstream of PigR-regulated genes. I found 
a particular 7 bp sequence in the PigR-regulated promoters examined, which, in promoters with 
identified transcription start sites, is 6-8 bp from the predicted -35 element. This suggests that 
the conserved sequence, which we tentatively call the PigR response element (PRE), may be 
found at all PigR-regulated promoters and may allow PigR to function to positively regulate the 
promoter. There are a number of ways in which recognition of this motif could occur, including 
that PigR could directly interact with this element, or that the binding of PigR to the RNAP-
associated MglA-SspA complex could promote the interaction between some other portion of 
RNAP, or the MglA-SspA complex itself, with the PRE.  
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 From these results, we hypothesize that the role of MglA and SspA in virulence gene 
expression may be principally to serve as a point of contact for PigR to influence RNAP activity 
and positively regulate a specific set of genes. This hypothesis is consistent with a number of 
pieces of data, specifically (i) the direct interaction between PigR and the MglA-SspA complex, 
(ii) the requirement of MglA for PigR to associate with promoter regions, (iii) the positive 
regulation by PigR of a subset of the MglA regulon, and (iv) the similar virulence phenotypes of 
cells lacking MglA, SspA, or PigR.  
 Results from the transcriptomic data in Chapter 2 suggest that MglA, but not PigR, may 
play a role in negatively regulating genes, specifically, those with σ32-controlled promoters. A 
possible explanation for this might be that the MglA-SspA complex promotes formation of σ70-
containing RNAP holoenzyme but not formation of the σ32-containing holoenzyme. By 
influencing the competition between σ factors for core RNAP, the MglA-SspA complex would 
effectively decrease transcription from σ32-dependent promoters and potentially even increase 
transcription from σ70-dependent promoters. In other organisms, it is known that SspA homologs 
influence the transcription of genes controlled by specific σ factors (De Reuse and Taha, 1997; 
Hansen et al., 2003; Yin et al., 2013). It is possible that in these other organisms and in F. 
tularensis, SspA functions to influence gene expression by altering σ factor competition.  
 As described in Chapter 3, I used ChIP-Seq to identify putative regulons for many other 
transcription factors in F. tularensis. The majority of transcription factors in F. tularensis have 
been implicated in virulence, and I examined each of these, along with the entire family of 
annotated LysR-type transcription regulators.  
 The transcription factor PmrA has been demonstrated to positively regulate genes on the 
FPI (Mohapatra et al., 2007; Sammons-Jackson et al., 2008), yet I did not detect PmrA at key 
promoters on the FPI. However, I was able to detect PmrA at the pigR promoter and previous 
transcriptomic analyses indicated that PmrA positively controls pigR expression (Mohapatra et 
al., 2007; Sammons-Jackson et al., 2008). This suggests that pigR is a direct target of PmrA. 
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Since PigR is present at promoters on the FPI and has been shown to influence FPI gene 
expression, it follows that PmrA may positively regulate FPI gene expression indirectly, by 
promoting pigR expression.  
 The identification of PmrA, IclR, and the LysR-type transcription regulator FTL_1568 at 
many genomic regions, both promoter and non-promoter regions, suggests that these factors 
may not always act as canonical transcription regulators. Rather, the abundance and location of 
the ChIP-Seq peaks of PmrA, IclR, and FTL_1568 suggests that they may play a role in 
chromosomal organization as NAPs. As transcription factors continue to be examined on a 
genome-wide level by ChIP-Seq, it is becoming increasingly recognized that they may be found 
at non-canonical locations. At least some of these sites of association may be attributed to 
particular factors acting, not only as canonical transcription factors, but also as NAPs (Dillon and 
Dorman, 2010). A role for transcription factors in chromosomal organization is perhaps not 
surprising, given that many factors can recognize both specific and degenerate motifs and, in 
binding the DNA, can alter the physical orientation of the DNA molecule within the cell. 
Additionally, F. tularensis is only thought to encode one well-described NAP, the HU homolog 
HupB. Given the lack of annotated proteins with NAP function in F. tularensis, identifying 
several within this work would seem to be a reasonable expectation.  
 I investigated the location of the iron-dependent repressor Fur, not because it has 
explicitly been demonstrated to be important for virulence, but because FPI gene expression 
has been shown to increase under conditions of limited iron (Buchan et al., 2008; Deng et al., 
2006; Lenco et al., 2005); increased gene expression under iron limitation is a hallmark of de-
repression by Fur. Previous studies implied that Fur may be responsible for the increase in FPI 
gene expression under low iron conditions and suggested the specific locations with which Fur 
might associate to influence FPI gene expression (Deng et al., 2006; Lenco et al., 2005). 
However, my results do not indicate that Fur is found at the FPI, suggesting that Fur does not 
directly associate with the FPI. Additionally, my analysis of Fur location suggests a F. tularensis-
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specific variation of the motif with which Fur associates. This specific motif is not found near FPI 
promoters. I do find Fur at the fsl operon, which has been shown to be repressed by Fur under 
conditions of high iron and has been identified as an important virulence factor in a number of 
screens. Thus, while Fur does not appear to directly influence FPI gene expression, I confirmed 
that it does appear to act directly to regulate another described virulence locus, the fsl operon.  
 In order to determine why OxyR and FTL_0040 are important for virulence, I examined 
their putative regulons to identify genes previously implicated as encoding virulence factors. I 
found that both OxyR and FTL_0040 appear to regulate multiple virulence-associated genes, 
suggesting that, rather than regulating one specific virulence factor, they are responsible for the 
coordinate regulation of multiple factors involved in pathogenesis.  
 We reasoned that, since infection and survival in a host cell is a complex multi-step 
process, there is likely to be significant regulation of transcription factors themselves. In fact, I 
found many transcription factors at the promoters of genes encoding other transcription factors. 
I examined the putative regulons of each factor for other transcription factors and was able to 
discern a network of potential regulation among the transcription factors. This network model 
suggests that several factors are ultimately responsible for regulating the expression of not only 
a number of transcription factors, but consequently, a large number of putative virulence factors.  
 My studies, focused on examining the location of transcription factors in association with 
the genome, provide us with more than the putative regulons for each virulence-associated 
transcription factor in F. tularensis. By determining the locations at which MglA, SspA and PigR 
are found, we have been able to revise our model suggesting how these transcription factors 
regulate virulence gene expression. For specific transcription factors, we have been able to 
suggest alternate functions. And we have gained insight into the architecture of virulence control 
in F. tularensis; we have shed light on the coordinate regulation of genes implicated in virulence, 
as well as the regulation of the genes that encode the transcription factors themselves. 
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Together, these data have provided a framework for understanding how virulence may be 





 Chapters 2 and 3 describe the identification of the genomic locations for thirty-one F. 
tularensis transcription factors. These studies have yielded a wealth of information with respect 
to transcription regulation in F. tularensis. However, the mechanism by which MglA, SspA, and 
PigR regulate virulence gene expression remains unclear. Additionally, while we have proposed 
putative regulons for all of the studied transcription factors, we do not know to what extent or 
manner these factors affect their putative regulons. Accordingly, this section includes a 
discussion of potential future experiments to explore these, and other, questions.  
 
Does the MglA-SspA complex influence σ factor competition? 
 The SspA homolog found in several other organisms seems to function, as a dimer, by 
promoting expression from genes controlled by particular σ factors. In Escherichia coli, SspA 
was found to associate with RNAP containing σ70 but not core RNAP or σS-containing RNAP. 
Our data suggest that in F. tularensis, MglA may function to inhibit transcription from σ32-
regulated promoters. However, our data do not address whether or not the change in σ factor 
competition promoted by MglA and SspA might lead to an increase in transcription from σ70-
dependent promoters. We hypothesize that the presence of the MglA-SspA complex promotes 
the formation of RNAP containing σ70, and in doing so, decreases the amount of core RNAP 
available to associate with σ32. Thus, in the absence of MglA, the competition between σ factors 
for the limited pool of RNAP is altered; without MglA, more core RNAP would be available to 
interact with σ32, allowing for increased transcription from σ32-regulated promoters.  
To more directly test if the increased expression from σ32-regulated promoters results 
from an increase in σ32 binding to σ32-regulated promoters, one could quantify the amount of 
σ32-regulated promoter DNA immunoprecipitated by σ32 in wild-type cells in comparison to cells 
lacking MglA. This would indicate that there is a difference in the amount of σ32 available in the 
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cell to associate with σ32-regulated promoters. However, this would not entirely rule out the 
possibility that MglA directly binds to, and represses, σ32-regulated promoters. 
In order to determine if loss of MglA has a direct effect on the amount of RNAP 
holoenzyme containing a particular σ factor, one could immunoprecipitate RNAP and determine 
the relative amounts of σ32 and σ70 associated with RNAP in cells with MglA compared to cells 
lacking MglA. This could be done using the strain in which the β′ subunit of RNAP is 
synthesized with a tandem affinity purification (TAP) tag, which was previously used to identify 
MglA, SspA, and σ70 associated with RNAP in F. tularensis (Charity et al., 2009). 
Immunoprecipitating more σ32-associated with RNAP in the absence of MglA than in the 
presence of MglA would be consistent with the MglA-SspA complex affecting σ factor 
competition, although it would not directly suggest a mechanism by which the complex 
promotes formation of the σ70-containing holoenzyme. In this case, further genetic and 
biochemical assays would be necessary to elucidate the mechanism through which the MglA-
SspA complex functions. Note that it is not currently known which subunit (or subunits) of RNAP 
is (are) contacted by the MglA-SspA complex. Biochemical or genetic (bacterial two-hybrid) 
studies could in principle determine where the MglA-SspA complex contacts RNAP, and could 
reveal whether the MglA-SspA complex might specifically interact with the σ70 subunit of RNAP.  
A corollary of our hypothesis, that the MglA-SspA complex may function to promote the 
formation of RNAP containing σ70, is that we would not expect the MglA-SspA complex to be 
associated with RNAP containing σ32. To directly test if the MglA-SspA complex is associated 
with RNAP containing σ32, one could immunoprecipitate σ32-containing RNAP and examine the 
associated proteins for the presence of either MglA or SspA. This could be done by generating 
a strain in which σ32 is synthesized with a TAP tag. The absence of MglA and SspA associated 
with σ32-containing RNAP would further suggest that the MglA-SspA complex specifically 
interacts with σ70-containing RNAP. A similar immunoprecipitation could be performed using σ70 
synthesized with a TAP tag as a control for the ability to detect MglA and SspA; if similar ratios 
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of RNAP subunits are associated with both σ factors, but MglA and SspA are not associated 
with σ32, this would provide evidence that the MglA-SspA complex only associates with σ70-
containing RNAP. However, one would have to demonstrate that the cells that produce TAP-
tagged σ factors contain the same amount of MglA and SspA.  
 
Does the PigR response element (PRE) confer regulation by PigR? 
 The identification of a specific sequence in PigR-regulated promoters, 6-8 bp from the -
35 element, suggests that this motif, the PRE, may be an element which allows the activity of a 
promoter to respond to the presence of PigR. One could test this by introducing a reporter gene, 
such as lacZ, under the control of a PigR-regulated promoter, into strains with and without PigR. 
We expect that, using a PigR-regulated promoter with an intact PRE, lacZ expression in cells 
containing PigR would be significantly higher than in cells that did not contain PigR. However, if 
significant changes are made to alter the PRE, we expect that reporter gene expression would 
only be significantly affected in cells that produce PigR. One could also test this by introducing 
the PRE into a non-PigR regulated promoter and seeing whether the modified promoter now 
becomes responsive to PigR.  
 It is important to reiterate that, in the case that the PRE does function as a PigR 
response element, this does not necessarily mean that PigR must bind or contact the PRE 
directly to promote gene expression at promoters with a PRE. It is possible that the presence of 
PigR affects RNAP to allow a specific domain of RNAP to contact the PRE and promote 
transcription. The C-terminal domain of the α subunit of RNAP (αCTD) has been found to 
contact a region upstream of the -35 element, and could be appropriately positioned to contact 
the PRE.   
 An indirect measure of determining if the PRE allows control by PigR would be to 
determine if all of the PigR-regulated promoters contain a PRE. However, the PRE motif, as 
currently defined, is only 7 bp, of which only 3 bp are completely conserved; the PRE is likely to 
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be found frequently throughout the genome. In order to firmly establish that both the PRE 
sequence and location, with respect to transcription start site, are conserved at all PigR-
regulated promoters, one would have to identify all the transcription start sites throughout the 
genome, which could be done using RNA-Seq.  
 
Can we correlate transcription factor location with transcription factor regulation? 
 In this study, we have identified putative direct targets, or regulons for each transcription 
factor examined. However, these data do not indicate if the association of a transcription factor 
with a particular location results in gene regulation. In fact, genes found to be regulated by 
PmrA and IclR in previously published transcriptomic studies do not correlate well to genes 
found near the ChIP-Seq peak for each factor. It is entirely possible that the presence of a factor 
at a particular location does not have any regulatory consequences; it is equally possible that 
the lack of overlap between regulated genes and genes associated with a ChIP-Seq peak is due 
to technical differences between experiments. Thus, the natural complement of ChIP-Seq 
analysis is transcriptomic analysis; identifying those genes whose expression changes in the 
absence of the transcription factor would allow us to suggest connections between the presence 
of a specific factor at a specific region and any associated changes in gene expression. 
Transcriptomic analyses of factors could be done at the whole-genome level by RNA-Seq using 
strains that lack a particular transcription factor.   
 Analysis of the regulon of select transcription factors by analyzing transcript abundance 
would also allow us to test and refine our model of regulation by transcription regulators. While 
we currently know which transcription factors may be directly influencing other transcription 
factors, the ChIP-Seq peaks identified are agnostic with respect to positive or negative 
regulation. A much greater understanding of the virulence control network could be gained by 




Could we assess transcription factor location at the whole-genome level? 
 In this study, we have determined the transcription factor locations for a larger proportion 
of total encoded transcription factors than any known study to date, reporting ChIP-Seq peaks 
for 70% of all known transcription factors in Francisella tularensis. If we consider that RNAP is a 
single transcription factor, we have assessed approximately 83% of transcription factors and 
only 11 of the total 40 remain to be examined. By performing ChIP-Seq on the remaining 11 
factors, we could obtain a whole-genome view of transcription factor association in a single 
organism. This may allow us to determine how many promoters in an organism are actually 
regulated by transcription factors other than RNAP. It also may provide further insight into any 
additional proteins important for chromosomal organization.  
 
Could performing ChIP-Seq in vivo or under alternate conditions identify additional 
targets? 
 We have essentially taken a snapshot of transcription regulation within F. tularensis in a 
particular condition at a particular stage of growth. While FPI-encoded virulence genes are 
expressed under these conditions, our growth conditions are unlikely to accurately mimic the 
range of environments which F. tularensis is exposed to, nor are they likely to mimic the 
conditions found in the intracellular environment, when survival of F. tularensis relies on the 
appropriate regulation of virulence factor production. In fact, in vitro growth media for F. 
tularensis have been reported which appear to be more similar to an in vivo environment than 
the media which we use (Hazlett et al., 2008). Under alternate conditions, it is likely that some of 
the transcription factors we have studied associate with different genomic regions and different 
target genes. If we examined transcription factor location in the context of other growth 
conditions, or in an in vivo model system (such as within macrophage), we may gain significant 
insights into how particular transcription factors are regulated and function to regulate target 
genes and virulence factors.  
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Performing ChIP-Seq using cells from an infection model, or in vivo ChIP-Seq, would 
yield the direct targets of virulence-associated transcription factors while they are in the 
processes of regulating pathogenesis. Transcriptomic analyses have successfully been 
performed in macrophage cell lines (Bent et al., 2013; Wehrly et al., 2009), which may be the 
most practical option with the technology we have currently. It should be noted that the 
significant technical challenge of in vivo ChIP-Seq would still be obtaining sufficient 
immunoprecipitated DNA for sequencing. Each F. tularensis cell can have hundreds of 
thousands of copies of a particular transcript, but each cell contains only a single chromosome. 
At best, each cell can only yield a single fragment for each site of transcription factor 
association. However, detection methods continue to improve and in vivo ChIP-Seq would give 
us a greater understanding of how virulence factors are regulated in an intracellular context, 
yielding insight into the extent to which transcription factor location differs between in vitro and 
in vivo conditions.  
For three factors, we failed to identify any ChIP-Seq peaks. There are a number of 
possible reasons for the lack of ChIP-Seq peak detection. It is possible that the addition of the 
epitope tag significantly interfered with the function or DNA binding of these factors. Alternately, 
it is possible that under the conditions of our experiments, the three factors were not made. 
Because each transcription factor examined is under the control of its native promoter and the 
conditions under which the native promoter is active have not been explored, it is possible that 
the protein levels of some transcription factors were very low or nonexistent. Consistent with this 
idea, detecting epitope-tagged protein was unsuccessful for several transcription factors; the 
addition of DNA encoding the epitope tag had to be confirmed at the DNA level. One protein 
which did not ChIP-Seq successfully, encoded by the locus FTL_1216, has recently been found 
to be highly upregulated at the transcript level in macrophages (Bent et al., 2013). Finding this 
factor highly upregulated in an infection model reiterates its importance in virulence and 
suggests that, rather than the protein not having any direct targets, we have been unsuccessful 
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at identifying them. In order to successfully define the regions of association for the factors that 
do not yet have any associated ChIP-Seq peaks, we could perform ChIP-Seq on cells grown in 
alternate conditions or in vivo, after validating protein production.  
 Overproduction of transcription factors is another strategy we could utilize to gain insight 
into the potential targets of a particular transcription factor, specifically for those factors that do 
not yet have any associated ChIP-Seq peaks. This approach has been successful in the past 
(Davies et al., 2011), and, if protein association with its direct targets relies mostly on affinity of 
the protein for a particular DNA site, an abundance of protein could potentially allow us to 
saturate the factor’s target sites. However, if a given transcription factor requires the presence 
of another factor to bind or associate with the DNA, or can only associate with regions that are 
not bound by another highly expressed transcription factor, we may not achieve a complete 





 A significant proportion of transcription factors encoded by F. tularensis are utilized to 
coordinately control the regulation of putative virulence factors, and these transcription factors 
themselves are subject to a network of regulation. MglA, SspA, and PigR, factors critical for 
intracelluar growth and survival, are found at essentially all promoters. The MglA-SspA complex 
may influence gene expression by playing a role in promoting formation of σ70-containing RNAP 
and also by providing a point of contact for PigR with the RNAP complex. PigR, in concert with 
MglA and SspA, acts as a positive regulator of gene expression and appears to be regulated by 
a number of factors. PigR, together with MglA and SspA, regulates pigR expression, as does 
PmrA and the small molecule ppGpp; OxyR, IclR, and FTL_1568 are all also detectable at the 
pigR promoter by ChIP-Seq, although the potential regulatory consequences of these 
associations is currently unknown. The PmrA, FTL_1568, and IclR proteins are found 
associated with many locations that are non-canonical for transcription factors, potentially 
indicating an alternate role for these factors in chromosomal organization. The LysR-type 
transcription regulators OxyR and FTL_0040 appear to coordinately regulate a number of 
putative virulence factors. Together, these studies allow for the generation of a model that 
suggests how transcription factors important for virulence are themselves controlled, which 
features a significant amount of potential autoregulation. The data presented here yield insights 
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Figure S1. Proteins associated with the FPI. Genomic position is indicated on the X-axis by F. 
tularensis LVS locus number; gray boxes represent genes, which are above the black line if they are 
encoded on the plus strand and below the black line if they are encoded on the minus strand. 
Representative tracks illustrating the density of normalized mapped sequencing reads after ChIP-Seq of 
β′ + rif, σ70, MglA, SspA, PigR, PmrA, IclR, FTL_1568, and Fur are depicted on the Y-axis. Areas of 
significantly enriched reads, referred to here as peaks, are indicated by the horizontal gray boxes below 
the read density plot and sites of maximum enrichment are indicated by the red lines. Putative promoter 
regions, which are areas with significant enrichment of β′ + rif, σ32, or σ70 association with the 
chromosome, are indicated by the purple horizontal boxes above the genomic position markers. PmrA is 
not enriched at either the iglA or pdpA promoter, unlike β’ + rif, σ70, MglA, SspA, and PigR. IclR and 


















































































Table S1. Transcription factors in F. tularensis LVS 
LVS1 U1122 SCHU S43 Gene Name Product 
FTL_0034 - FTT1659   hypothetical protein 
FTL_0040 FTN_0031 FTT1652c - LysR family transcriptional regulator 
FTL_0062 FTN_0101 FTT1684 - transcription regulator 
FTL_0261 FTN_0264 FTT0350 rpoA1 DNA-directed RNA polymerase, α 
subunit 
FTL_0370 FTN_0395 FTT0868c arsR arsenical resistance operon repressor 
FTL_0415 - FTT1307c - hypothetical protein 
FTL_0428 FTN_0434 FTT0908 parB chromosome partition protein B 
FTL_0449 FTN_0480 FTT0383 pigR transcription factor PigR 
FTL_0552 FTN_1465 FTT1557c pmrA two-component response regulator 
FTL_0610 FTN_1416 FTT1446 rho transcription termination factor Rho 
FTL_0616 FTN_1412 FTT_1442
c 
rpoA2 DNA-directed RNA polymerase, α2 
subunit 
FTL_0632 FTN_1393 FTT_1426 - ArsR family transcriptional regulator 
FTL_0643 FTN_1384 FTT1418c nusB transcription antitermination factor NusB 
FTL_0662 FTN_1363 FTT1401 lexA prophage repressor protein 
FTL_0689 FTN_1274 FTT1255c - transcriptional regulator araC family 
protein 
FTL_0742 FTN_1179 FTT1202 - LysR family transcriptional regulator 
FTL_0844 FTN_1099 FTT1119 - LysR transcriptional regulator family 
protein 
FTL_0851 FTN_1092 FTT1112c rpoH RNA polymerase σ32 factor 
FTL_0895 FTN_1054 FTT0627 hupB Histone-like protein HU form B 
FTL_1014 FTN_0959 FTT0556c oxyR oxidative stress transcriptional regulator 
FTL_1050 FTN_0913 FTT1035c rpoD RNA polymerase σ70 factor 
FTL_1079 FTN_0889 - - helix-turn-helix family protein 
FTL_1126 FTN_0795 FTT1076 hipB transcriptional regulator / hipB? 
FTL_1176 FTN_1300 FTT1285c - LysR transcriptional regulator family 
protein 
FTL_1185 FTN_1290 FTT1275 mglA macrophage growth locus, subunit A 
FTL_1193 FTN_1282 FTT1267 - LysR transcriptional regulator family 
protein 
FTL_1216 FTN_0866 FTT0985 - hypothetical protein FTL_1216 
FTL_1222 FTN_0858 FTT0977c - hypothetical protein FTL_1222 
FTL_1231 FTN_0850 FTT0970 - hypothetical protein FTL_1231 
FTL_1276 FTN_0811 FTT0477 birA Bifunctional protein BirA 
FTL_1293 FTN_1534 FTT0359 - hypothetical protein FTL_1293 
FTL_1364 FTN_0720 FTT0748 iclR hypothetical protein FTL_1364 
FTL_1474 FTN_0665 FTT1313c greA transcriptional elongation factor 
FTL_1533 FTN_0613 FTT0703 rpoZ DNA-directed RNA polymerase, ω 
subunit 
FTL_1568 FTN_0583 FTT0492c - LysR family transcriptional regulator 
FTL_1606 FTN_0549 FTT0458 sspA stringent starvation protein A, regulator 
of transcription 
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Table S1. Transcription factors in F. tularensis LVS, continued 
FTL_1631 - - - hypothetical protein 
FTL_1634 - FTT1594 - LysR family transcriptional regulator 
FTL_1743 FTN_1567 FTT0145 rpoC DNA-directed RNA polymerase, β' 
subunit 
FTL_1744 FTN_1568 FTT0144 rpoB DNA-directed RNA polymerase, β 
subunit 
FTL_1749 FTN_1573 FTT0139 nusG transcription antitermination protein 
NusG 
FTL_1810 FTN_1661 FTT0049 nusA transcription elongation factor NusA 
FTL_1831 FTN_1681 FTT0030c fur ferric uptake regulation protein 
FTL_1967 FTN_1779 FTT1803c trpR trp operon repressor 
1Gene locus number in F. tularensis subsp. holarctica strain LVS 
2Gene locus number in F. tularensis subsp. novicida strain U112 
3Gene locus number in F. tularensis subsp. tularensis strain SCHU S4 
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